SMOKING CESSATION IN CANCER SURVIVORS: EXPLORING PSYCHOSOCIAL WELLBEING, BELIEFS ABOUT SMOKING, AND E-CIGARETTE USE by Symes, Yael
 
SMOKING CESSATION IN CANCER SURVIVORS: EXPLORING PSYCHOSOCIAL 
WELLBEING, BELIEFS ABOUT SMOKING, AND E-CIGARETTE USE 
 
Yael Rose Symes 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 







Shelley D. Golden 
Kurt M. Ribisl 
Marcella H. Boynton 
Deborah K. Mayer 










































Yael Rose Symes 













Yael Rose Symes: Smoking cessation in cancer survivors: Exploring psychosocial wellbeing, 
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Smoking after a cancer diagnosis is associated with various negative health outcomes and 
existing smoking cessation interventions for cancer survivors have not been effective in 
influencing cessation rates. The purpose of this dissertation is to better understand smoking-
related factors uniquely influenced by receiving a cancer diagnosis that could be used to create 
more successful cessation interventions for cancer survivors.  
Manuscript 1 used time-to-event analysis to assess whether psychosocial factors—
distress, health-related quality of life (HRQOL), and perceived social support—at one year after 
diagnosis predicted whether survivors successfully quit smoking and the amount of time it took 
to quit in a longitudinal nationally representative sample of long-term cancer survivors from the 
American Cancer Society Study of Cancer Survivors (SCS-I; n = 341). Manuscript 2 assessed 
whether survivors of tobacco-related cancers reported higher perceived severity of health 
problems from smoking compared to survivors of non-tobacco-related cancers and explored 
whether this relationship was stronger for recently-diagnosed versus long-term survivors in a 
cross-sectional national sample from the Population Assessment of Tobacco Health—PATH—
study (n = 433). Manuscript 3 identified e-cigarette use prevalence and reasons for use among 
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cancer survivors who smoke (n = 433) and compared to smokers without a prior cancer diagnosis 
(n = 10,872) in the PATH study. 
In Manuscript 1, survivors with low physical HRQOL were significantly less likely to 
quit smoking and took several more years to quit than survivors with high physical HRQOL. In 
Manuscript 2, survivors of tobacco-related cancer reported higher perceived severity of smoking 
than survivors of non-tobacco-related cancer and this relationship was the same for recently-
diagnosed and for long-term survivors. In Manuscript 3, nearly 6 in 10 cancer survivors who 
smoke had used e-cigarettes, and nearly one quarter of survivors were currently doing so; rates 
were similar in those never diagnosed. The majority of both groups (>71%) reported using e-
cigarettes for perceived health-related reasons—including smoking reduction. 
Clinicians may want to assess physical HRQOL, perceived severity of smoking, and 
discuss the research on the efficacy of e-cigarettes as a quitting strategy with their patients who 
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CHAPTER 1: OVERVIEW AND SIGNIFICANCE 
1.1 Purpose of Dissertation  
 Cancer survivors—particularly survivors of tobacco-related cancers (e.g., lung and head 
and neck)—smoke at higher rates than the general population.1 Smoking after a cancer diagnosis 
is associated with lower rates of survival, higher rates of recurrent disease and secondary tumors, 
and decreased efficacy of treatment.2-6 The purpose of this dissertation is to better understand 
smoking-related factors uniquely influenced by receiving a cancer diagnosis that could be 
targeted in smoking cessation interventions to improve quit rates and ultimately reduce morbidity 
and mortality outcomes in this population. This dissertation examines psychosocial predictors of 
both quitting smoking and the length of time it takes to quit, diagnosis of a tobacco-related 
cancer as a correlate of beliefs about the harms of smoking, and the use of a perceived harm 
reduction strategy—e-cigarettes—in cancer survivors who smoke. Manuscript 1 uses time-to-
event analysis to assess whether psychosocial factors (e.g., psychological distress, health-related 
quality of life, perceived social support) at one year after diagnosis predict whether survivors 
successfully quit smoking and the amount of time it takes a survivor to quit in a longitudinal 
nationally representative sample of long-term cancer survivors diagnosed within 10 years. 
Manuscript 2 assesses whether survivors of tobacco-related cancers report higher perceived 
severity of health problems from smoking compared to survivors of non-tobacco-related cancers 
in a cross-sectional national sample of survivors. This paper further explores whether the 
observed relationship between diagnosis of tobacco-related cancer and perceived severity of 
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smoking varies by time since diagnosis (i.e., if the relationship is stronger for recently-diagnosed 
versus long-term survivors). Last, Manuscript 3 documents e-cigarette use and reasons for e-
cigarette use among cancer survivors who are also smokers of combustible cigarettes, and 
compares the prevalence and reasons for use to those for smokers never diagnosed with cancer.  
The knowledge gained from this dissertation will provide guidance for interventions that 
could be designed specifically for cancer survivors. For example, if psychosocial factors such as 
health-related quality of life (HRQOL) strongly predict if and when survivors quit after 
diagnosis, then smoking cessation interventions could target survivors with poor HRQOL with 
more intensive long-term support. Additionally, if survivors of tobacco-related cancers perceive 
higher severity of health problems from smoking than survivors of non-tobacco-related cancers, 
this suggests that interventions need to especially target the beliefs of survivors of non-tobacco-
related cancers. Finally, it would be useful for clinicians to know if cancer survivors who smoke 
are using e-cigarettes as a possible smoking cessation tool, so that misconceptions about the 
cessation efficacy and harms of e-cigarettes can be addressed in clinical encounters. In sum, the 
knowledge from this dissertation will inform which modifiable outcomes and subpopulations to 
target in smoking cessation interventions to better meet the needs of cancer survivors. 
1.2 The Problem of Smoking After Cancer Diagnosis  
 The smoking prevalence of cancer survivors after diagnosis ranges widely from 7-51%1,7-
10 because the prevalence differs by type of cancer.10 Survivors of tobacco-related cancers (e.g., 
cervical,1,11-13 bladder,13 and lung cancer13) report the highest rates of smoking, in part because 
they were more likely to smoke before diagnosis.13 Cervical cancer survivors smoke at the 
highest rates of any cancer site—with rates ranging from 33-51%.1,11,13 One large national study 
in the United States that included cancer survivors with a wide range of years since diagnosis 
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found that 27% of bladder cancer survivors smoke after diagnosis compared to 23.5% of lung 
cancer survivors.13 Smoking rates are lowest in prostate, breast, colon, and melanoma cancer 
survivors, who smoke at rates ranging from 7-12%.1,11,12 Depending on cancer site, the smoking 
rate in cancer survivors as a group is as high or higher than the smoking rate of the general 
United States population,10 which the Centers for Disease Control and Prevention (CDC) 
estimate to be 15%.14  
Smoking after a cancer diagnosis is associated with various negative health outcomes. A 
recent review of the negative consequences of smoking after cancer diagnosis reported that 
current smoking is associated with lower survival in lung, head and neck, breast, prostate, 
esophageal, cervical, endometrial, bladder, ovarian, leukemia, and lymphoma cancer patients.15 
Additionally, smoking after cancer is related to higher rates of recurrent disease5,16,17 and more 
primary tumors.16-23 Continued smoking after cancer diagnosis is also associated with decreased 
efficacy of cancer treatment,3,17 increased treatment-related complications and symptom burden 
(e.g., more sleep problems, higher pain severity, more fatigue),6,15,17,24-27 and lower HRQOL.15,27-
30 Those who smoke after a cancer diagnosis also have an increased risk for comorbid conditions 
such as myocardial infarction, congestive heart failure, and diabetes.15,18,31 Thus, the morbidity 
and mortality associated with smoking after a cancer diagnosis constitutes a significant public 
health problem.  
1.3 Smoking Cessation  
There are multiple health benefits of quitting smoking, and the percentage of cancer 
survivors who smoke and who want to quit ranges from 49-69%.11,12,32,33 Tobacco dependence is 
a chronic disease that often requires multiple quit attempts and repeated intervention to alter.34 
The majority of tobacco users will experience multiple periods of relapse (i.e., a return to regular 
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smoking)—up to 80% of smokers relapse.35 There is a distinction between “relapse” and a 
“lapse” or “slip”: the latter refers to a brief return to smoking that does not turn into regular 
smoking.34 Smoking cessation is commonly measured as continuous abstinence, which refers to 
when participants in a study do not smoke from their quit date to a designated outcome point 
(e.g., 6 months after the quit date).34 Smoking cessation is also commonly measured as a point 
prevalence—i.e., tobacco use occurrence within a set period (usually 7 days).34 Smoking 
cessation in this dissertation refers to whether someone who had been a regular smoker reported 
that they had completely quit smoking.  
1.4 Significance of the Research  
There is a paucity of smoking cessation treatment programs in oncology settings.15,36 A 
recent meta-analysis of 10 randomized-controlled trials found that the few smoking cessation 
interventions for cancer survivors that have been implemented did not significantly influence 
smoking cessation rates in both the short and long term.37 A meta-analysis of randomized-
controlled trials found that cessation intervention strategies that were effective in the general 
population were not effective in cancer survivors (Sheeran et al., under review). The authors of 
three systematic reviews of smoking cessation interventions for cancer survivors recommend that 
cancer survivors receive the gold standard for smoking cessation treatment in the general 
population: a combination of medication—mainly nicotine replacement therapy (NRT) and 
varenicline— and behavioral therapies such as counseling and reading materials.37-39 Yet cancer 
survivors might have unique needs, motivations, and beliefs about smoking that could influence 
quitting outcomes, and should therefore be incorporated into quitting interventions designed for 
them. This dissertation identifies factors that might be important to target in smoking cessation 
interventions designed specifically for cancer survivors. For instance, understanding factors 
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particularly relevant to cancer survivors (e.g., poor psychosocial wellbeing or specific cancer 
types) could help public health professionals identify the survivors most in need of intensive 
cessation interventions. Additionally, knowing if cancer survivors are more prone to trying e-
cigarettes as a cessation aid can prompt patient-provider discussions about the evidence of the 
efficacy and harms of e-cigarettes. This knowledge could better equip healthcare clinicians in 
their recommendations for smoking cessation strategies for their patients. This dissertation 
investigates several risk factors and cessation strategies among cancer survivors who smoke that 
could illuminate ways to create more effective smoking cessation interventions: psychosocial 
factors including distress, perceived social support, HRQOL; cancer type (tobacco-related or 
non-tobacco-related) and perceived severity of harms from smoking; and e-cigarette use and 
reasons for use.  
Manuscript 1: Psychosocial Factors and Smoking Cessation in Long Term Survivors.  
Karam-Hage and colleagues argue for the need for smoking cessation interventions to be 
tailored to the specific needs of cancer survivors, paying special attention to psychosocial factors 
that can interfere with tobacco cessation treatments as well as treatments for cancer.39 There are 
several potential psychosocial predictors of smoking outcomes in the general population—
including psychological distress, HRQOL, and perceived social support40-42—that are likely 
directly affected by receiving a cancer diagnosis.43-45 Understanding who is most at risk for 
continuing to smoke after a cancer diagnosis based on measures of psychosocial wellbeing will 
allow public health professionals to know whom to deliver more intensive cessation 
interventions. Also, knowing if these psychosocial factors predict how long it takes survivors to 
quit could help clinicians identify ideal times for cessation support in the years following after 
diagnosis. Japuntich et al. stress the need for studies to evaluate the relationship between 
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psychosocial functioning and smoking cessation outcomes in longer-term survivors, because of 
the high rate of smoking relapse in this group.46 It takes survivors on average 8.8 years to 
successfully quit after diagnosis47 and many survivors make multiple quit attempts.34,46,48 
Understanding the trajectory of cessation among those survivors who do not quit smoking 
immediately after diagnosis, and whether psychosocial factors that can be assessed as part of 
routine healthcare screening predict that trajectory, can guide the type and timing of clinician 
cessation support. Manuscript One of this dissertation uses time-to-event analysis in a 
longitudinal national dataset to investigate the following research question:  
Research Question 1.1: Do psychosocial factors at one year after diagnosis predict 
whether survivors quit and the length of time it took to quit smoking within 10 years from 
diagnosis?  
Manuscript 2: Diagnosis of Tobacco-Related Cancer and Perceived Severity of Health Problems 
from Smoking.  
 
Although initial smoking rates are higher among those diagnosed with a tobacco-related 
cancer, several studies have found that smokers who are diagnosed with tobacco-related cancers 
quit smoking at higher rates than smokers diagnosed with other cancer types.47,49,50 There is little 
investigation of mechanisms that might explain the difference in quit rates between survivors of 
tobacco-related and non-tobacco-related cancers. Higher perceived severity of health problems 
from smoking (e.g., believing that smoking is harmful to health) is associated with smoking 
cessation in cancer survivors49,51 and might help explain the relationship between cancer type 
and smoking cessation. Survivors of tobacco-related cancers might have higher perceived 
severity of health problems from smoking than survivors of non-tobacco-related cancers if they 
are more likely to attribute their cancer to their tobacco use and if they are more likely to be 
advised by their loved ones and clinicians to quit. If survivors of non-tobacco-related cancers 
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have lower perceived severity of the harms of continued smoking, then cessation efforts could 
focus on changing the smoking beliefs of this group. Further, it is possible that this difference in 
perceived severity between the two groups is particularly pronounced immediately following 
diagnosis when health and mortality are most salient. This knowledge could further inform how 
to help cancer survivors quit smoking years after they are diagnosed, for example, by focusing 
intervention efforts to increase perceived severity of health problems from smoking in survivors 
of non-tobacco-related cancers soon after diagnosis when their perceived severity is significantly 
lower than that of survivors of tobacco-related cancers. Manuscript Two investigates the 
following research question:  
Research Question 2.1: Among current smokers, do survivors of tobacco-related cancers 
report higher perceived severity of health problems from smoking than survivors of non-
tobacco-related cancers and does the relationship between diagnosis of tobacco-related 
cancer and perceived severity from smoking vary by time since diagnosis? 
Manuscript 3: Dual cigarette and e-cigarette use in cancer survivors 
 
Cancer survivors who smoke, as compared to smokers without cancer, are particularly 
motivated to quit smoking.39 Smokers in the general population often perceive and use e-
cigarettes (also known as electronic cigarettes, electronic nicotine delivery systems—ENDS, and 
vapor pens) as a strategy to reduce or eliminate combustible cigarette use,52-54 but research on 
whether cancer survivors do the same is limited. The evidence of e-cigarettes as a successful quit 
strategy is modest and controversial. Meta-analyses that have included the results of 
observational and randomized control trials found that e-cigarette use was associated with 
significantly lower odds of quitting smoking combustible cigarettes,55,56 yet other meta-analyses 
which included only randomized control studies found that e-cigarette users were more likely to 
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quit if their e-cigarettes contained nicotine versus if they did not contain nicotine.57,58 There is 
one published randomized control trial that compared e-cigarettes to another smoking cessation 
method—nicotine replacement therapy (NRT), but this trial did not find significant differences 
between the two intervention arms and59 and had significant methodological limitations.56 Thus, 
as the literature stands, there is inconclusive evidence that e-cigarettes help smokers—including 
both cancer survivors and those never diagnosed—quit combustible cigarettes. In addition to the 
limited efficacy of e-cigarettes as a smoking cessation tool, there are known short-term harms of 
e-cigarette use (e.g., burns and other injuries),60 although more research is needed to document 
long-term health consequences of using e-cigarettes specifically in cancer survivors, including 
the potential adverse interactions of e-cigarettes and cancer therapies.61 The authors of three 
systematic reviews of smoking cessation interventions for cancer survivors recommend that 
cancer survivors receive evidence-based cessation support including a combination of FDA-
approved medication—mainly nicotine replacement therapy and varenicline— and behavioral 
therapies such as counseling and reading materials.37-39 
Little is known about e-cigarette use and reasons for use among cancer survivors who 
want to quit smoking conventional cigarettes and who might be more motivated to use e-
cigarettes as a smoking cessation or reduction tool than those without a history of cancer. There 
is only one published study (by Kruse et al.) to my knowledge that statistically compared 
differences in ever and current e-cigarette use between currently smoking cancer survivors and a 
population never diagnosed with cancer.62 Kruse and colleagues found that among current 
smokers, ever and current e-cigarette use were not different between cancer survivors and the 
population without a medical comorbidity.62 This study, however, did not consider demographic 
differences between the two groups. The majority (87%) of cancer survivors in the U.S. are 
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diagnosed at or over age 50,63 whereas younger age is associated with higher e-cigarette ever 
use.64,65 It might be important to account for differences in age to determine whether survivors 
are using e-cigarettes at rates beyond what we would expect for their age group. There is also no 
research on differences in e-cigarette use by cancer type. Survivors of tobacco-related cancers 
might be differentially motivated to quit smoking combustible cigarettes because of the well-
known association between smoking and tobacco-related cancers (e.g., lung cancer). Last, there 
are no studies to our knowledge that detail the various reasons that cancer survivors report using 
e-cigarettes and how these reasons compare to those of a general population of smokers. If e-
cigarette use rates are relatively high for cancer survivors, and particularly for survivors of 
specific tobacco-related cancers, then clinicians who treat cancer survivors may need to discuss 
the current evidence about the cessation efficacy and harms of e-cigarettes with their patients 
who are trying to quit or reduce smoking. Manuscript Three of this dissertation explores the 
following research questions:  
Research Question 3.1: Does the prevalence of e-cigarette use among current 
combustible cigarette smokers vary by cancer survivorship status and cancer type? 
Research Question 3.2: Do reasons for e-cigarette use among current combustible 





CHAPTER 2: THEORETICAL FRAMEWORK  
2.1 Constructs from Three Health Behavior Theories 
The theoretical model of the first manuscript in this dissertation outlines mechanisms that 
might explain how psychosocial factors are related to both receiving a cancer diagnosis and to 
smoking cessation outcomes, including quitting and the length of time it takes to quit. The model 
is informed by the Health Belief Model (HBM),66 the Theory of Planned Behavior (TPB),67 and 
the Cognitive-Social Health Information Processing model (C-SHIP).68,69 The theoretical model 
of the second manuscript in this dissertation illustrates how the perceived severity of health 
problems from smoking could explain the relationship between a diagnosis of tobacco-related 
cancer and smoking cessation, and is informed by the HBM and the C-SHIP model. The research 
questions of manuscript three of this dissertation are exploratory, and thus do not have a 
theoretical underpinning.  
The HBM is a value expectancy theory that assumes individuals are rationally motivated 
to perform a health behavior to avoid negative health outcomes.66 The central premise of the 
HBM is that individuals’ beliefs about costs and benefits of a health behavior combined with 
their perceived threat of inaction (i.e., perceived severity and susceptibility) and their self-
efficacy for the specific behavior, predicts whether or not that person will perform the behavior. 
The TPB assumes that the best predictor of a health behavior is the intention to perform that 
behavior, which is determined by the attitude toward the behavior (i.e., benefits and barriers), the 
perception of social norms regarding the behavior, and perceived control over the performance of 
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the behavior.67 The C-SHIP model is an overarching theoretical framework specific to cancer 
prevention and control that describes how individuals cognitively and affectively process health 
information and how this information translates into health behaviors.68,69 Before a cancer 
survivor engages in efforts to quit smoking, according to C-SHIP, the survivor evaluates their 
health beliefs, expectancies, values, goals, and affective response. For example, a survivor might 
quit smoking only if they perceive that their health will be at risk if they continue to smoke and 
that they will improve their health if they quit smoking.  
The combination of constructs from the HBM, the TPB, and the C-SHIP model provides 
an overall framework that recognizes the importance of attitudinal beliefs (i.e., perceived 
benefits and barriers of quitting), the perceived severity of health problems from smoking, and 
the intention to quit smoking in smoking cessation. Several constructs from each of these 
theories overlap, but they all stress the importance of beliefs about engaging in the behavior 
(e.g., quitting smoking) and the outcomes of the behavior. All of constructs from each of the 
three theories and their potential relevance to smoking cessation in cancer survivors are 
summarized in Table 2.1. My goal was to develop conceptual models that illustrated potential 
links between psychosocial variables (Manuscript 1) and cancer type (Manuscript 2) and 
cessation behaviors in cancer survivors, rather than to test all potential predictors of cessation. I 
therefore identified constructs from Table 2.1 that were the most plausible links between the 
ideas I explored in each manuscript. As a result, I did not employ all constructs for any one 
theory, and several key components of some theories (e.g., self efficacy, perceived behavioral 
control, subjective norms) were not part of my conceptual models.  
Additionally, several researchers have argued that the constructs I chose to include in the 
theoretical models for Manuscripts 1-2 are critical constructs related to smoking cessation 
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outcomes in cancer survivors. In one study, Westmaas and colleagues found that the odds of 
quitting smoking in survivors were higher for those with higher perceived severity of smoking-
related health problems and those who perceived more benefits of quitting. In that study, the 
odds of quitting smoking were lower for survivors who perceived more barriers to quitting.70 
Another study that identified correlates of continued smoking after diagnosis in head, neck, and 
lung cancer patients found that smokers, compared to those who quit, reported lower risk 
perceptions (i.e., lower awareness of the adverse health effects associated with continued 
smoking), lower benefits of quitting, and higher barriers to quitting.51 In a study of patients of 
mixed cancer types, current smokers with intentions to quit had higher perceived health risks of 
smoking than current smokers with no intention to quit smoking.71 A qualitative study of lung, 
liver, stomach, nasopharynx, or colorectal cancer survivors found that an important barrier to 
quitting smoking in current smokers was limited perceived benefits to quitting and the perception 
that the barriers to quitting outweighed the benefits.72 Berg and colleagues explained that 
smoking behavior in cancer survivors results from the intention to smoke, which is a function of 
attitudes toward smoking.8 In sum, attitudes about quitting, perceived severity of health problems 
from smoking, and the intention to quit smoking are all important constructs that could influence 





Table 2.1: Theoretical Constructs 
Theory Construct Definition Relevance  
HBM Perceived 
susceptibility  
Belief about the risk of getting a 
disease (part of perceived threat) 
Cancer survivors with high 
social support might be more 
likely to perceive they are 
susceptible to health harms if 
they continue smoking if their 
social network advises them to 
quit.  
Perceived severity Belief about the health 
consequences of the 
behavior/disease (part of 
perceived threat) 
A cancer survivor’s social 
network can provide health 
information about the health 
risks of continued smoking after 
diagnosis (e.g., death), which in 
turn could increase a survivor’s 
perceived severity of health 
problems from smoking. 
Survivors of tobacco-related 
cancer might report higher 
perceived severity of smoking 
than survivors of non-tobacco-
related cancer.  
Perceived benefits Belief in the efficacy of the 
behavior to reduce harm 
Survivors with high distress and 
low HRQOL might perceive the 
benefits of quitting to be low if 
they use smoking as a way to 
cope. Those with high social 
support might learn about the 
pros of quitting (e.g., to improve 
health and prevent disease) from 
their social network.  
Perceived barriers Belief about costs (tangible and 
psychological) of the behavior 
Survivors with high distress and 
low HRQOL may not feel that 
they are able to quit smoking 
because they do not have other 
resources to cope. The barriers 
of quitting might also outweigh 
the benefits for those who are 
trying to quit but who have 
consistently relapsed, because 
relapsing may add to distress. 
Low social support could be a 
barrier to quitting if survivors 
perceive they have no one to 
help them quit.  
Cues to action Strategies to instigate action Survivors with high social 
support might receive reminders 
to quit from their social network.  
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Theory Construct Definition Relevance  
Self-efficacy  Confidence in one’s ability to 
take action 
Survivors with high social 
support might have higher self-
efficacy to quit smoking if they 
know they have people they can 
rely on to help them quit.  
TPB Attitude Beliefs about performing the 
behavior (evaluation of 
behavioral outcomes) 
Survivors with high distress and 
low HRQOL might have more 
negative beliefs about quitting if 
they use smoking as a way to 
cope. Those with high social 
support might have more 
positive attitudes about quitting 
if their social network 
encourages them to quit.  
Subjective norm Includes normative beliefs (how 
important individuals in social 
network feel about the behavior) 
and motivation to comply to 
norms 
Survivors with high social 
support might be exposed to 
more normative beliefs about 
quitting if their loved ones 
advise them to quit. Survivors 
with high social support might 
also be motivated to comply to 
norms if they do not want to let 
their loved ones down. Survivors 
of tobacco-related cancer might 
also feel more normative 




Factors outside individual control 
that may affect intentions and 
behaviors (barriers and extent 
barriers will make it difficult to 
perform the behavior) and agency 
to perform the behavior.  
Survivors with high distress and 
low HRQOL may not have other 
coping resources to help them 
quit. The barriers of quitting 
might also outweigh the benefits 
for those who are trying to quit 
but who have consistently 
relapsed, because relapsing may 
be add to distress. Low social 














Theory Construct Definition Relevance  
Intention to 
perform behavior 
Deciding to perform behavior; the 
most important determinant of the 
behavior 
It is possible that survivors with 
poor psychosocial functioning 
take longer to quit because it 
might take them longer to decide 
to make a serious quit attempt 
(because of different attitudes 
about quitting and perceived 
severity) than survivors with 
better psychosocial functioning. 
Survivors of tobacco-related 
cancer might be more likely to 
intend to quit than survivors of 




Strategies and constructs for 
encoding health risks (perceived 
vulnerability)  
Cancer survivors with high 
social support might be more 
likely to perceive threats to 
continued smoking if their social 
network advises them to quit.  
Health beliefs and 
expectancies   
Specific beliefs and expectations 
activated in health information 
processing. Includes expectancies 
about outcomes and self-efficacy 
expectancies  
Survivors with better 
psychosocial functioning might 
be more likely to believe they 
will improve their health if they 
quit. Survivors with high social 
support might have higher self-
efficacy to quit smoking if they 
know they have people they can 
rely on to help them quit. 
Affects Emotions  Survivors with poor HRQOL 
and high distress may feel 
anxious, ashamed, hopeless, and 
fatalistic about quitting.  
Health goals and 
values 
Desired health outcomes and their 
importance and goals for 
achieving these outcomes 
Survivors with better 
psychosocial functioning may 
feel it is important to live a good 
quality of life, and decide to quit 
smoking to achieve optimal 
health, whereas survivors with 
worse psychosocial functioning 
may feel it not worthwhile to 






2.2 Theoretical Application In Manuscripts 1 and 2 
Manuscript 1: Psychosocial Factors and Quitting Smoking in Long-Term Cancer Survivors. 
Psychosocial factors—specifically a survivor’s level of psychological distress, HRQOL, 
and perceived social support—might be particularly important in shaping smoking-related beliefs 
in cancer survivors because many survivors face unique issues precipitated by their cancer 
diagnosis and treatment that might impact psychosocial wellbeing (e.g., feelings of guilt, shame, 
fear of recurrence, reduced HRQOL, and social isolation). These psychosocial factors also likely 
influence attitudes (benefits and barriers to quitting smoking) and the perceived severity of 
health problems from smoking and in turn, intentions to quit smoking, which influence quitting 
outcomes.  
A cancer diagnosis can cause distress in the form of anxiety, fear of recurrence, and 
feelings of guilt, stigma or shame—which can last for years after diagnosis.43,73,74 Distress might 
influence a person’s attitudes (i.e., benefits and barriers) of smoking cessation. Those who are 
distressed may not feel that they are able to quit smoking because they do not have other 
resources to cope with their cancer-related stress; thus the lack of coping resources acts as a 
major barrier to quitting. Cancer survivors might use smoking as a way to cope with cancer-
related stress. Those who self-medicate their distress with smoking might perceive the benefits of 
quitting to be low if they use smoking as a way to cope. The barriers of quitting might also 
outweigh the benefits for those who are trying to quit but who have consistently relapsed, 
because relapsing may be add to distress. Indeed, in a healthy population, current smokers who 
made an unsuccessful quit attempt in the past year reported higher levels of psychological 
distress than those who did not report making an unsuccessful quit attempt.75 The negative 
feelings from an anticipated possible relapse might also be a strong barrier to quitting.  
 
 17 
Many cancer survivors will experience reductions in HRQOL, which can include pain, 
fatigue, respiratory problems, changes in body image, problems in sexual functioning at some 
point after diagnosis that can persist for years after they are diagnosed.44,76 A cancer survivor’s 
HRQOL might influence their attitudes toward smoking cessation. For example, the benefits of 
quitting might be to low and the barriers of quitting might be high if survivors with poor 
HRQOL use smoking as a way to cope with their physical limitations.  
Individuals diagnosed with cancer often receive an initially high level of social support at 
the time of diagnosis, but over time this support often diminishes and some cancer patients 
become socially isolated after treatment ends,77 which can make it more difficult for them to get 
the support they need to help them quit smoking. Social support can directly and indirectly 
influence smoking cessation. In the direct link, social resources can be a source of motivation 
and reinforcement to quit.78 Westmaas and colleagues argue that the functions of social support 
can be specific to smoking abstinence.79 For instance, informational support can include advice 
about how to cope with withdrawal or general advice on how to cope with stress; emotional 
support can include listening to the venting of emotions about the difficulty of quitting or about 
stressful emotions in general; and instrumental support can consist of providing nicotine 
replacement therapy or helping the person with chores that might reduce their overall stress and 
distract them from smoking.79 These functions of social support could also influence smoking 
cessation indirectly by shaping a cancer survivor’s perceived severity of smoking and attitudes 
(i.e., perceived benefits and barriers to quitting). A cancer survivor’s social network can provide 
health information about the health risks of continued smoking after diagnosis, which in turn 
could increase a survivor’s perceived severity of health problems from smoking. Cancer 
survivors’ attitudes about smoking could also be influenced by social support. A study of 290 
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adults found that emotional and instrumental support provided by a close family member or 
friend was significantly associated with behavioral intention to perform goal behaviors specific 
to each participant and attaining the goal behavior.80 The authors of that study argue that aspects 
of social support are likely associated with the precursors to behavioral intention (e.g., attitude 
about the behavior). There are no studies to my knowledge that specifically tested if perceived 
social support is associated with attitudes and perceived severity of health problems from 
smoking in the general population or in cancer survivors. However, Zhang and colleagues found 
that the effects of received social support for leisure time physical activity on intention to 
perform physical activity were mediated by attitudes on physical activity.81 Thus, perceived 
social support likely directly and indirectly influences behaviors such as smoking cessation by 
shaping perceived severity of health problems from smoking and attitudes toward smoking.   
 In sum, many cancer survivors experience issues related to their diagnosis and treatment 
(e.g., guilt and shame related to their diagnosis, fear of disease recurrence, physical limitations, 
and social isolation), which can reduce their psychosocial health (i.e., increase distress, reduce 
HRQOL and perceived social support). Poor psychosocial functioning in turn could reduce 
negative attitudes about quitting and perceived severity of health problems from smoking, which 
could reduce their intention to quit smoking and likelihood of successfully quitting. 
Although less research examines the length of time it takes to quit smoking, this outcome 
may also be associated with quit intentions. It is possible that cancer survivors with worse 
psychosocial functioning, who perhaps have more negative attitudes about quitting, more 
positive attitudes about smoking, and lower perceived severity of harms from smoking, might 
experience more periods of relapse and thus take longer to quit smoking than survivors with 
better psychosocial functioning. It is also possible that survivors with poor psychosocial 
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functioning take longer to quit because it might take them longer to decide to make a serious quit 
attempt than survivors with better psychosocial functioning.  
Theoretical Conceptual Model for Manuscript 1  
 
 
Manuscript 2: Diagnosis of Tobacco-Related Cancer and Perceived Severity of Health Problems 
from Smoking. 
 
The perceived severity of health problems from smoking is an important precursor to 
quitting smoking. Perceived severity of health problems from smoking might help explain the 
relationship between diagnosis of tobacco-related cancer and smoking cessation. If survivors of 
tobacco-related cancers have higher perceived severity of health problems from smoking 
compared to survivors of non-tobacco-related cancers, they might be more likely to have an 
intention to quit and thus quit at higher rates. The health risks of smoking after diagnosis might 
be especially salient to survivors of tobacco-related cancers because of the well-known link 
between tobacco use and lung and head and neck cancer. Survivors of tobacco-related cancer 
who attribute their cancer diagnosis to their own tobacco use might perceive higher severity of 






















attribute their cancer to tobacco use. In addition, many survivors of tobacco-related cancer might 
be advised by their loved ones and healthcare clinicians to quit, which in turn might promote 
higher perceived severity of smoking than survivors of non-tobacco related cancers who are 
perhaps not as frequently advised by their healthcare clinicians to quit. A clinician’s advice to 
quit is as an important motivator for quit attempts in the general population of smokers.34,82,83  






















CHAPTER 3: MANUSCRIPT 1- 
THE IMPACT OF PSYCHOSOCIAL FACTORS IN PREDICTING SMOKING 
CESSATION IN LONG-TERM CANCER SURVIVORS: 
A TIME-TO-EVENT ANALYSIS 
 
 
Objective. Smoking poses significant health risks to cancer survivors. Receiving a cancer 
diagnosis may heighten distress, and reduce social support and health-related quality of life 
(HRQOL), each of which could inhibit successful smoking cessation. Understanding longitudinal 
associations between these psychosocial factors and successful cessation could help clinicians 
better tailor cessation interventions for their patients. Methods. We conducted time-to-event 
analyses using data from the American Cancer Society Study of Cancer Survivors-I (SCS-I)—a 
longitudinal nationwide study—to examine the relationship between psychosocial factors and 
cessation likelihood in cancer survivors diagnosed 7-10 years prior. We also assessed whether 
psychosocial factors were associated with the amount of time it took survivors to quit following 
diagnosis. Results. Cancer survivors with high physical HRQOL were more likely to quit 
smoking within 10 years of their cancer diagnosis than survivors with low physical HRQOL, 
controlling for cancer type and number of comorbid conditions at baseline (HR = 1.96; 95% CI: 
1.10-2.70; p=.02). Survivors with high physical HRQOL also took less time to quit than 
survivors with low physical HRQOL. Survivors of tobacco-related cancers with low physical 
HRQOL were the least likely group to quit. No significant relationships between the other 
psychosocial predictors and cessation outcomes were observed. Conclusions. Smoking cessation 
programs are needed for all cancer survivors who smoke, but survivors with low physical 
HRQOL may need even more intensive long-term smoking cessation interventions with multiple 
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check-in points after smoking relapses. Cessation interventions that include strategies to mitigate 
physical symptoms in those with poor physical HRQOL deserve consideration in research and 
practice. 
Introduction 
The prevalence of smoking among cancer survivors ranges widely, from 7% to 51%, 
depending on the type of cancer.1,8 Researchers estimate that between 14% to 64% of cancer 
survivors who smoked prior to their cancer diagnosis continue to smoke after their 
diagnosis.7,10,47,84 Smoking after a cancer diagnosis is associated with various adverse health 
outcomes including lower survival,2,4 higher rates of recurrent disease,5 more new primary 
cancers,21 decreased efficacy of cancer treatment,3 increased treatment-related complications and 
symptom burden,6 and lower health-related quality of life (HRQOL).27,29 There is a paucity of 
smoking cessation treatment programs in oncology settings15,36 and a meta-analysis of 
randomized-controlled trials found that current smoking interventions for cancer survivors were 
ineffective, despite that fact that cessation interventions do work for the general population 
(Sheeran et al., under review). Thus, cancer survivors might have unique needs that could 
influence quitting outcomes, and understanding factors distinctly influenced by receiving a 
cancer diagnosis could help create more successful smoking cessation interventions for cancer 
survivors. 
There are several psychosocial factors that are related to smoking status in the general 
population of smokers—including psychological distress, health-related quality of life 
(HRQOL), and perceived social support.40-42 These psychosocial factors are also directly affected 





The diagnosis of cancer and the threat to life associated with it can be anxiety-provoking 
to many patients,73 possibly making more difficult for those who smoke to quit. Many survivors 
of various cancers experience a fear of disease recurrence, which can be lasting and 
psychologically distressing.43 Some cancer patients might feel stigma, guilt, or shame because of 
their diagnosis—especially if they feel they have caused their cancer by smoking.74 Many people 
use tobacco as a way to cope with distress and regulate mood85 and cancer survivors with high 
distress may feel that they do not have sufficient resources to cope with their cancer-related 
distress. One study with head and neck cancer patients found that continuing to smoke after 
diagnosis was associated with higher distress one year later, although no work has investigated 
distress as a predictor of cessation over long periods of time in cancer surivors.86    
Health-Related Quality of Life (HRQOL)  
Many cancer survivors experience reductions in HRQOL (i.e., a person’s self-rated 
perception of health, which can include pain, fatigue, respiratory problems, changes in body 
image, problems in sexual functioning),87,88 at some point after they are diagnosed, which can 
persist for years.44,76 A systematic review of cross-sectional studies of lung cancer survivors 
found that continued smoking was associated with lower physical and mental HRQOL.76 In a 
national survey, Blanchard et al. found that breast, prostate, and colorectal survivors diagnosed 
within 10 years who did not smoke had significantly higher HRQOL than those who did.89 There 
have been no studies to our knowledge that have prospectively tested whether HRQOL predicts 





Perceived Social Support 
Individuals diagnosed with cancer often receive an initially high level of social support at 
the time of diagnosis, but over time this support often diminishes and some cancer patients 
become socially isolated after treatment ends,77 which can make it more difficult for them to get 
the support they need to help them quit smoking. A longitudinal study found that breast cancer 
patients reported larger decreases in perceived social support (i.e., a person’s perception of the 
resources available to them from their social interactions)45 after two years from diagnosis 
compared to age-matched controls who reported more stable social support during that time.90 
Another longitudinal study that followed newly diagnosed survivors found that perceived 
emotional support decreased during the year after diagnosis.91 Perceived social support can be a 
source of motivation and reinforcement to quit smoking.78 In a cross-sectional analysis, lower 
levels of perceived emotional social support were associated with smoking after diagnosis in a 
sample of lung cancer patients.92 A cross-sectional study of short and long-term survivors of 
various cancer types found that higher perceived social support was associated with higher odds 
of quitting smoking after diagnosis.50 Longitudinal research is needed to assess the relationship 
between perceived social support and smoking cessation after diagnosis in long-term cancer 
survivors.  
Overview of Current Study 
Most investigations on psychosocial factors and smoking cessation in cancer survivors 
have been cross-sectional and focused on recently treated survivors of specific cancers.93 Not 
much is known about whether psychosocial factors such as distress, HRQOL or perceived social 
support predict smoking cessation in long-term survivors of various cancer types. Survivors on 
average take 8.8 years to successfully quit after diagnosis among those who have quit47 and 
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many make multiple quit attempts.46 It is common for survivors who quit smoking immediately 
after diagnosis to later experience a smoking relapse after they complete their cancer treatment.94 
Identifying psychosocial risk factors associated with continued smoking after a cancer diagnosis, 
which could be easily assessed as part of routine clinical care, could help public health 
professionals identify the survivors most in need of intensive cessation interventions. 
Additionally, knowing if these psychosocial factors predict how long it takes survivors to quit 
could help clinicians identify ideal times for cessation support in the years following after 
diagnosis. For example, smoking intervention efforts delivered immediately post diagnosis may 
need to be extended, especially among those with poor psychosocial functioning. 
The present study uses time-to-event analyses in a longitudinal dataset of cancer 
survivors to examine if psychosocial factors assessed one year after diagnosis predict: 1) whether 
cancer survivors quit smoking after diagnosis and 2) how the probability of quitting changes over 
time. We adjust for the type of cancer diagnosis—whether a cancer is tobacco-related or not—
and number of comorbidities (e.g., heart disease, diabetes, breathing problems) because these are 
medical factors uniquely related to smoking cessation in cancer survivors.47,49 We hypothesize 
that survivors with higher psychological distress, lower HRQOL, and lower perceived social 
support at one year after diagnosis will be less likely to quit smoking and will take longer to quit 
compared to those with lower psychological distress, higher HRQOL, and higher perceived 
social support. 
Methods  
Data Source and Sample  
We tested our hypotheses using data from participants represented in both Wave 1 and 3 
of the American Cancer Society Study of Cancer Survivors-I (SCS-I). This longitudinal 
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nationwide study surveyed cancer survivors by mail or telephone roughly 1, 2, and 9 years after 
diagnosis. Wave 1 data were collected between 2000 and 2003, and Wave 3 data were collected 
between 2010 and 2011. Cancer survivors were selected through stratified random sampling of 
11 state cancer registries. To be eligible for this study, survivors had to be at least 18 years old at 
diagnosis; diagnosed with one of the 10 most highly incident cancers at the time of participant 
recruitment (i.e., breast, prostate, bladder, uterine, skin melanoma, colorectal, kidney, non–
Hodgkin lymphoma, ovarian, and lung cancer); diagnosed with a local, regional, or distant 
Surveillance, Epidemiology, and End Results (SEER) summary stage; diagnosed between 
January 2000 and September 2003, and fluent in English or Spanish. Minority race/ethnicities, 
survivors below age 55, and survivors of cancers with moderate or low survival (e.g., kidney, 
lung cancer) were oversampled. The Institutional Review Board of Emory University approved 
SCS-I, with additional approvals for each state. Additional information about the methodology of 
SCS-I is available elsewhere.95 
Smoking status and history (e.g., age at quit) was assessed only at Wave 3. Participants 
were asked whether they had smoked at least 100 cigarettes in their lifetime, and if so, whether 
they currently smoked every day or some days. Those who were not current smokers but had 
smoked at least 100 cigarettes were asked their age at quitting. Of the 2,752 cancer survivors 
who answered smoking questions at Wave 3, 246 indicated they were current smokers, and an 
additional 95 indicated that they had quit after they were diagnosed with cancer. These 341 
cancer survivors comprise the analytic sample for this study. Sample sizes for each analysis were 






Length of time between cancer diagnosis and quitting—outcome variable:  
The difference in years between participants’ age at diagnosis, and their age when they 
subsequently quit was calculated by subtracting a survivor’s age when they quit smoking from 
their age at diagnosis (reported at Wave 1). Values ranged from 1-10 years. Current smokers’ 
completion of the Wave 3 assessment counted as their “event,” although they had not yet quit at 
that assessment because the survival time in time-to-event analysis is at least as long as the 
period that each participant was followed (i.e., these data are right-censored).96 Thus, for current 
smokers, survival time was coded as the survivor’s age in years at Wave 3 minus the survivor’s 
age at diagnosis. We also created a separate variable representing censorship status, as is 
typically done in time-to-event analysis,96 to differentiate current smokers who were diagnosed 
10 years ago from survivors who quit 10 years after diagnosis.  
Psychological Distress—predictor variable:  
Psychological distress was assessed in Wave 1 using the 37-item Profile of Mood States-
Short Form scale (POMS-SF).97 For each item, respondents indicated on a 5-point scale from 0 
“not at all” to 4 “extremely” how much they had been feeling each mood (e.g., uneasy, grouchy, 
nervous, annoyed) during the past two weeks. Scores were derived for total negative mood and 
for six factor-based subscales. The following six subscales with Cronbach’s α levels ranged from 
.85 to .95 include: Depression-Dejection; Vigor-Activity; Confusion-Bewilderment; Tension-
Anxiety; Anger-Hostility; Fatigue-Inertia. We obtained the total score by summing the subscale 
Depression-Dejection, Confusion-Bewilderment, Tension-Anxiety, Anger-Hostility, and 
Fatigue-Inertia scores minus the Vigor-Activity scores. Higher total scores indicate higher 
psychological distress with scores ranging from -24 to 111. Scores were dichotomized based on a 
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median split as done in previous research98 to aid in the interpretation of findings: scores at or 
below the median value of 10 were considered low psychological distress and scores above the 
median were considered high psychological distress.  
Health-Related Quality of Life—predictor variable:  
HRQOL was assessed in Wave 1 using the Medical Outcomes Study Short Form-36 
(MOS SF-36).99 MOS SF-36 is a 36-item, commonly used self-report tool that consists of eight 
subscales including physical functioning (e.g., bathing or dressing yourself), role-physical (e.g., 
as a result of physical health, had difficulty performing work), bodily pain, general health (e.g., 
my health is excellent), vitality (e.g., have a lot of energy), social functioning (e.g., frequency 
health problems interfered with social activities), role-emotional (e.g., as a result of emotional 
problems, extent accomplished less than you would like), and mental health (e.g., felt calm and 
peaceful). Cronbach’s α levels for subscales ranged from .85-.91. The MOS SF-36 is scored on 
two component summary scales for physical (PCS) and mental (MCS) health, which are both 
summed over all eight subscales (items related to physical health are negatively weighted in the 
MCS and items related to mental health are negatively weighted in the PCS), from which we 
derived two dichotomous variables for physical and mental HRQOL. The range was 13 to 68 for 
the PCS and 11 to 66 for the MCS. For each, survivors who scored 1 standard deviation at or 
below a national normalized mean (≤ 40) were considered to have low HRQOL and those who 
scored above that value were considered to have high HRQOL; this categorization of the MCS 
and PCS has previously been used in the literature.100  
Perceived Social Support—predictor variable:  
Perceived social support was assessed in Wave 1 with the Multidimensional Scale of 
Perceived Social Support (MSPSS).101 This 12-item self-report inventory measures perceived 
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adequacy of social support from significant others, family, and friends on a 7-point Likert-type 
scale ranging from 1 “very strongly disagree” to 7 “very strongly agree.” Example items include, 
“There is a special person with whom I share my joys and sorrows;” “My family really tries to 
help me;” and “I can talk about my problems with my friends” Scores from all items were 
summed to create a total score, where higher scores indicate higher perceived social support; 
scores ranged from 12 to 84 (Cronbach’s α =.99). Scores were dichotomized for analyses using 
median split as done in a previous study102: scores at or below the median score of 5.83 were 
considered low social support and score above the median were considered high social support. 
Tobacco-related cancer diagnosis—control variable:  
Diagnosis of a tobacco-related cancer was recorded through the cancer registry data and 
confirmed by self-report in the Wave 1 survey. We created a dichotomous tobacco-related cancer 
variable based on the type(s) of cancer the participants reported having, using the classifications 
in the International Agency for Research on Cancer (IARC) guidelines,103 which has been used 
in previous studies.47,49 IARC guidelines consider tobacco-related cancers to include colorectal, 
bladder, kidney, and lung cancers, and non-tobacco-related cancers to include breast, prostate, 
uterine, skin melanoma, non–Hodgkin lymphoma, and ovarian cancers.  
Comorbid conditions—control variable:  
We also included number of comorbid conditions as a covariate in our models. In Wave 
1, participants indicated “yes” or “no” if they had been treated in the past five years for each of 
the following conditions: Alzheimer’s disease, Crohns disease, diabetes, high blood pressure, 
heart attack, other heart conditions, stroke, circulatory problems, arthritis, asthma, osteoporosis, 
enlarged prostate, frequent infections. We summed the number of comorbid conditions to create 
a comorbidity index that ranged from 0 to 13. 
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 Analytic Strategy  
We used time-to-event analysis—also known as survival analysis—to test our 
hypotheses. First, we ran separate Cox regression models regressing quitting smoking on each 
psychosocial factor, both without control variables (Model 1) and with control variables (Model 
2). We obtained a Hazard Ratio (HR) to indicate whether survivors with poorer psychosocial 
wellbeing were less likely to quit after diagnosis compared to those with better psychosocial 
wellbeing. We added an interaction with time for each psychosocial factor to assess if the data 
violated the proportional hazards assumption.96 We compared Kaplan Meier survival curves and 
their corresponding Log Rank p-value for each dichotomous Wave 1 psychosocial factor. The 
Kaplan Meier curves for each model illustrate how the probability of quitting after diagnosis 
differs based on the two levels of each predictor over time. To provide further insight into 
results, we conducted exploratory analyses to examine how any significant associations we 
observed differed by type of cancer (tobacco-related or non-tobacco-related). We incorporated 
the discrete nature of the data into the analyses using the “ties=exact” statement in SAS. Survey 
weights were incorporated for Wave 3 that adjusted for oversampled populations in the 
descriptive analyses but not in inferential analyses. We used SAS version 9.4 to conduct all 
analyses two-tailed with a critical alpha of .05. 
Results 
 Table 1 describes the characteristics of the sample. The majority of the sample were 
current smokers (68.2%), survivors of non-tobacco-related cancers (76%), female (53.4%), non-
Hispanic-White (88%), and had completed at least some college (60.7%). The mean age of the 
sample was 59.5 years (SE: 1.0). 
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 In unadjusted analyses (Table 2-Model 1), none of the psychosocial factors of interest 
were significantly associated with quitting smoking (Table 2). In adjusted analyses (Model 2), 
however, physical HRQOL was significantly associated with quitting. Those with high physical 
HRQOL at baseline were almost twice as likely to quit smoking within 10 years of diagnosis 
compared to those with low physical HRQOL, after adjusting for cancer type and number of 
comorbid conditions (HR = 1.96; 95% CI: 1.11-3.46; p=.02). These data did not violate the 
proportional hazard assumption. The unadjusted Kaplan Meier curve (Figure 3) illustrates that 
for those with high physical HRQOL, the increase in the probability of quitting started at two 
years after diagnosis and steadily increased over time. In those with poor physical HRQOL, the 
most noticeable initial increase in quitting occurred at six years from diagnosis. The unadjusted 
Kaplan Meier curves for psychological distress, perceived social support, and mental HRQOL 
(Figures 1-2, 4) all suggest that the probability of quitting smoking gradually increases for both 
low and high categories of groups over time, especially after four years from diagnosis.  
We plotted a survival curve for physical HRQOL on quitting, stratifying by cancer type, 
to further explore how the probability of how quitting changed over time for each level of 
physical HRQOL and cancer type (Figure 5). At each year after diagnosis within the timeframe 
of the study, survivors of tobacco-related cancers with high physical HRQOL were more likely 
to quit smoking than any other group. In all years except years 5-7 after diagnosis, survivors of 
tobacco-related cancers with low physical HRQOL were the least likely group to quit smoking. 
Additionally, the time at which the first increase in quitting occurred varied by both physical 
HRQOL and cancer type. The initial increase in quitting occurred two years post-diagnosis for 
survivors of both types of cancers who had high physical HRQOL. Among those with low 
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physical HRQOL, increases in quitting began 4 and 7 years post-diagnosis for tobacco-related 
and non-tobacco-related cancer survivors, respectively.  
Discussion 
 Of the four psychosocial variables that we examined, only physical HRQOL was 
significantly associated with smoking cessation and the time at which cessation occurred in the 
sample of cancer survivors. Specifically, we found that cancer survivors with low physical 
HRQOL one year after diagnosis were less likely to successfully quit smoking within ten years 
of diagnosis than survivors with high physical HRQOL, when controlling for cancer type and 
number of comorbid conditions. Survivors with low physical HRQOL also took longer to quit 
than survivors with high physical HRQOL. The first noticeable increase in the probability of 
quitting occurred at two years after diagnosis in survivors with high physical HRQOL compared 
to year six in survivors with low physical HRQOL. Survivors of tobacco-related cancer with 
high physical HRQOL were the most likely group to quit smoking, while survivors of tobacco-
related cancer with low physical HRQOL were the least likely group to quit.  
 These results suggest that cancer survivors with low physical HRQOL might use 
cigarettes as a way to cope with their pain and poor physical functioning. However, although we 
observed that low physical HRQOL one year after diagnosis is associated with lower quit rates 
over time, our research cannot make causal assertions about the nature of this association. It is 
possible that higher nicotine addiction and higher cigarette consumption both worsen physical 
HRQOL and make quitting more difficult. Research that accounts for these factors, as well as 
qualitative research studies with survivors with low physical HRQOL, are needed to better 
understand the unique barriers to quitting these survivors face.  
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Our results suggest that if future research corroborates our findings on HRQOL and 
cessation, it might be worthwhile for oncology clinicians to assess physical HRQOL in their 
patients and provide more intensive long-term cessation resources to smokers with poor physical 
HRQOL, who might have a particularly difficult time quitting smoking. Smoking cessation 
interventions that include strategies to mitigate physical symptoms in those with poor physical 
HRQOL (e.g., by incorporating acupuncture or occupational therapy to combat persistent fatigue 
and pain) deserve consideration in research and practice.  
More research is also needed to understand reasons why survivors with low physical 
HRQOL may take longer to quit than survivors with high physical HRQOL. Assessing various 
predictors and risks for smoking cessation several years after diagnosis might inform 
interventions to shrink the time window that it takes survivors with low physical HRQOL to quit. 
 In our exploratory analyses, we found that survivors of tobacco-related cancers with low 
physical HRQOL were the least likely group to quit smoking, though the reasons for this are 
unclear. Research is needed to examine the specific barriers to quitting experienced by survivors 
of tobacco-related cancer with lower physical HRQOL so that these survivors can be 
appropriately targeted in smoking cessation interventions.  
Our hypotheses on psychological distress, perceived social support, and mental HRQOL 
were not supported: we did not find a significant association between those psychosocial 
variables and quitting nor did it appear that those factors influenced the length of time until 
quitting in this sample. Although studies with the general population suggest each of these may 
be important predictors of smoking,40-42 they may change significantly over time in cancer 
survivors, so that any single observation of these factors may not sufficiently predict cessation. A 
systematic review of quality of life outcomes of long-term survivors of various cancer types 
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found that overall HRQOL increases over time after cancer diagnosis, although issues with 
physical HRQOL (e.g., pain, fatigue) can persist for years.44 Mental HRQOL at the time of 
diagnosis might therefore be related to quitting smoking in the first year of diagnosis, but the 
effects might taper off after one year as cancer survivors return to a more normal lifestyle. 
Alternatively, the effect sizes of these psychosocial factors on quitting may have been too small 
to detect in our sample. These analyses should be replicated in studies with larger sample sizes, 
and more observations of both predictors and smoking over time.  
Even among survivors of tobacco-related cancers with high physical HRQOL—the group 
most likely to quit smoking— the majority (56.5%) of respondents were still smoking 10 years 
following diagnosis. Exploring other predictors of quitting smoking in long-term survivors will 
be important to design more comprehensive interventions. Levels of anxiety or depressive 
symptoms, as well as specific social support for quitting have been linked to smoking outcomes 
in cancer survivors in past studies, and deserve more consideration in future research.8,71,104,105  
There are several strengths to this study. First, data came from a longitudinal national 
study of long-term (> 5 years) cancer survivors, which allowed us to use time-to-event analysis 
to identify not just who was less likely to quit smoking but also how much longer it took certain 
groups to quit, which has implications for when to intervene. Second, this study included 
survivors of various cancer types, which allowed us to examine how the probability of quitting 
smoking changed based on levels of each psychosocial factor and cancer type. This analysis 
further identified populations (e.g., survivors of tobacco-related cancer with low physical 
HRQOL) that might need more intensive cessation resources over time.  
 There are limitations of this study that are important to consider. The variable time since 
quitting was imprecisely measured because age at quitting was measured in years. Using years as 
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the unit of measurement might not reflect an accurate time of when survivors quit smoking. The 
yearly hazard ratio of quitting smoking, however, has been used in another time-to-event 
analysis study106 and we incorporated the discrete nature of the data into the analyses. More 
precise measures of the length of time until quitting in days or months, rather than in years, may 
help us better understand the best windows of opportunity for intervention. Second, smoking 
status was assessed retrospectively at a single time point. It would be informative for future 
studies to conduct these analyses with prospective data that contain multiple assessments of both 
psychosocial factors and smoking status over time to improve our understanding of this 
association. Last, this analysis relies on data from longtime cancer survivors. The 
generalizability of any findings from this work, however, has to be understood as applicable only 
to individuals who do survive 7-10 years post diagnosis. In our sample, participants in Wave 1 
with the following characteristics were more likely to remain in Wave 3: survivors of non-
tobacco-related cancer, those with lower comorbid conditions at Wave 1, lower psychological 
distress, higher mental and physical HRQOL, and higher perceived social support. The smoking 
rate was low in the Wave 3 sample (7.8%); if the people lost to follow-up were also particularly 
unlikely to quit smoking and were perhaps heavier smokers and had worse psychosocial 
outcomes, had we included them in the analytic sample, our results might have been different. 
Conclusions and Implications  
Survivors in this sample with low physical HRQOL were both less likely to quit and took 
several more years to quit than survivors with high physical HRQOL. These results suggest that 
should our findings be corroborated in future research, we recommend that smoking cessation 
programs explicitly provide cancer survivors with low physical HRQOL, and especially 
survivors of tobacco-related cancers, with intensive long-term smoking cessation interventions 
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with multiple check-in points after smoking relapses. Smoking cessation interventions might 
need to also include strategies to help cancer survivors with low physical HRQOL manage their 
symptoms (e.g., strategies that reduce pain and fatigue). Recognizing the importance of physical 
HRQOL as a predictor of smoking cessation and the amount of time it takes to quit could be an 
important step in creating more effective cessation interventions designed specifically for cancer 




Table 3.1: Characteristics of the Sample 
(n =341) 
Characteristic  N                         %/Mean/SEa Missing N (%) 
Smoking Statusb 
    Current smoker 
    Quit after diagnosis 
 
246                             68.2 
  95                             32.8 
     0 (0) 
 
      
Cancer Type 
    Tobacco-related 
    Non-tobacco-related 
 
111                             24.0 
229                             76.0 
     1 (0.3) 
 
      
Gender 
    Female  
    Male 
 
191                             53.4 
150                             46.6 
     0 (0) 
 
      
Race 
    Non-Hispanic White 
    Non-Hispanic Black 
    Hispanic 
    Other 
 
300                             88.0 
  24                             10.0 
  10                               1.4 
    5                               0.6 




      
Completed Education 
    Less than HS 
    HS graduate 
    Some college 
    College degree or more 
 
  36                             14.4 
101                             24.2 
117                             42.7 
  81                             18.0 




      
Age at Wave 1 341                             59.5 (1.0)      0 (0) 
Number of Comorbid 
Conditions at Wave 1 
338                               0.9 (0.1)       3 (0.8) 
Time Until Quit Smoking   95                 Median: 4.6 (0.8)       0 (0) 
Psychological Distress 297                             17.1 (1.5)     44 (12.9) 
HRQOL 
    PCS 
    MCS 
 
311                             47.7 (0.6)  
311                             46.3 (0.7) 
   30 (8.8) 
    
    
Perceived Social Support 323                               5.6 (0.1)    18 (5.3) 
a. Percentages and means/medians/SE are weighted.  





Table 3.2: Cox Proportional Hazard Models  
 
 Model 1  Model 2   
Characteristic Total Hazard Ratio 
95% CI 
P-Value Total Hazard Ratio 
95% CI 
P-Value 
Psychological Distress  
Cancer Type 
Comorbid Conditions	  
297 1.22 (0.78-1.91) 
           --- 










Perceived Social Support  
Cancer Type  
Comorbid Conditions 
323 1.14 (0.76-1.73) 
           --- 




319 1.16 (0.77-1.77) 





Physical HRQOL  
Cancer Type  
Comorbid Conditions 
311 1.54 (0.90-2.66) 
           --- 










Mental HRQOL  
Cancer Type  
Comorbid Conditions 
311 1.24 (0.78-1.97) 
           --- 










Notes: Reference categories: Psychological distress (high); Cancer type (non-tobacco-related); Perceived social 
support (low); Physical HRQOL (low); Mental HRQOL (low).  
Model 1: No control variables 
Model 2: Controls for cancer type and number of comorbid conditions; AICs were smaller in Model 2 




Figure 3.1: Unadjusted Kaplan Meier Survival Curve for Psychological Distress  
(n = 297) 
 







Figure 3.2: Unadjusted Kaplan Meier Survival Curve for Perceived Social Support  
(n = 323) 
 




























Figure 3.3: Unadjusted Kaplan Meier Survival Curve for Physical HRQOL  
(n = 311) 
 
 




Figure 3.4: Unadjusted Kaplan Meier Survival Curve for Mental HRQOL  
(n = 311) 
 




Figure 3.5: Survival Curve for Physical HRQOL Adjusted for Cancer Type 
(n = 311) 
 
 




CHAPTER 4: MANUSCRIPT 2- 
DIAGNOSIS OF TOBACCO-RELATED CANCER AND PERCEIVED SEVERITY OF 
HEALTH PROBLEMS FROM SMOKING IN CANCER SURVIVORS  
  
Purpose. Cancer survivors diagnosed with tobacco-related cancers (e.g., lung, head and 
neck) quit smoking at higher rates than those diagnosed with non-tobacco-related cancers (e.g., 
breast, prostate). Survivors of tobacco-related cancers—who are more likely to attribute their 
cancer to their tobacco use—might have higher perceived severity of health problems from 
smoking than survivors of non-tobacco-related cancers, which might in turn influence cessation. 
Understanding differences in smoking beliefs between the two groups could help clinicians 
target smoking cessation interventions. Methods. We conducted linear regression analyses using 
Wave 1 of the Population Assessment of Tobacco Health (PATH) study to examine differences 
in perceived severity of health problems from smoking between smokers who were survivors of 
tobacco vs. non-tobacco-related cancers. We then explored whether this difference varied by 
time since diagnosis. Results. We found that survivors of tobacco-related cancers reported 
higher perceived severity of health problems from smoking than other survivors (β = .25, p = 
.04) and this relationship was the same for recently diagnosed and long-term survivors. 
Conclusions. Our findings suggest that differences in quit rates between survivors of tobacco 
and non-tobacco-related cancers could at least in part be attributed to differences in perceived 




Smoking after a cancer diagnosis is associated with lower survival,2,4 higher rates of 
recurrent disease,5 more secondary tumors,19-23 decreased efficacy of cancer treatment,3 
increased treatment-related complications and symptom burden, 6,24,25 and lower quality of life 
(QOL).27-30 Smoking prevalence rates among cancer survivors after diagnosis range widely as a 
function of cancer type, with estimates ranging anywhere from 7-51%.1,8,12,13 Survivors of 
tobacco-related cancers (e.g., cervical, bladder, and lung cancer) report the highest rates of 
smoking after diagnosis (ranging from 27%-51%) in part because they were more likely to 
smoke before diagnosis.1,8,12,13 One study that aggregated smoking status across survivors of 
various tobacco-related cancers found that 51% continued to smoke after a cancer diagnosis.8 
Conversely, survivors of non-tobacco-related cancers such as prostate and breast cancer, tend to 
report low rates of smoking after diagnosis (7.7% and 11.9%, respectively).1 Although initial 
smoking rates are higher among those diagnosed with a tobacco-related cancer, several studies 
have found that smokers who are diagnosed with tobacco-related cancers quit smoking at higher 
rates than smokers diagnosed with other cancer types.47,49 These findings, however, are not 
universal. A large study found similar quit rates post-diagnosis for survivors of various cancer 
types, although lung and head and neck cancers were excluded from those analyses.107 There is 
little investigation on mechanisms that might explain the difference in quit rates between 
survivors of tobacco and non-tobacco-related cancers.  
The Health Belief Model66 and the Cognitive-Social Health Information Processing 
model (C-SHIP)68,69 posit that high perceived severity of health problems from smoking (e.g., 
believing that smoking is harmful to health) leads to higher intentions to quit smoking, and 
ultimately higher rates of smoking cessation. In a study by Westmaas et al., the odds of quitting 
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smoking after a cancer diagnosis were higher for those with higher perceived severity of 
smoking-related health problems.70 Another study that identified correlates of continued smoking 
after diagnosis in head, neck, and lung cancer patients found that those who continued to smoke 
versus those who quit smoking reported lower perceptions of risk of continued smoking (i.e., 
awareness of adverse health effects of continued smoking such as an increased risk in cancer 
recurrence).51 This evidence indicates that the perceived severity of health problems from 
smoking is an important construct related to smoking cessation outcomes in cancer survivors.  
The perceived severity of health problems from smoking might help explain the 
relationship between the diagnosis of tobacco-related cancer and smoking cessation. Survivors of 
tobacco-related cancers might have higher perceived severity of health problems from smoking 
than survivors of non-tobacco-related cancers if they are more likely to attribute their cancer to 
their tobacco use. In one study, lung cancer patients who smoked were more likely than breast 
and prostate cancer patients to believe their smoking behavior contributed to their cancer.74 In a 
qualitative study of lung, liver, stomach, nasopharynx, or colorectal cancer survivors who 
currently smoke, many of the survivors who were diagnosed with cancers other than lung cancer, 
reported that they were unaware of the association between their cancer diagnosis and smoking; 
some thought smoking is only associated with lung cancer.72 Additionally, because of the well-
known link between smoking and tobacco-related cancers,8,108 many survivors of tobacco-related 
cancer might be advised by their loved ones and clinicians to quit, which in turn might promote 
higher perceived severity of health problems from smoking. Survivors of non-tobacco related 
cancers are perhaps not as frequently advised to quit. In one study of long-term survivors of 
mostly breast, prostate, and gastric cancers who smoked at diagnosis found that almost 60% had 
not been advised to quit smoking by their clinicians.33 In contrast, lung and head and neck cancer 
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patients might be exposed to more recommendations to quit: a large study of lung cancer 
physicians found that 81% advise their patients who smoke to quit at their initial patient visit.109  
 To our knowledge, there are no published studies that explore if survivors of tobacco-
related cancers report higher perceived severity of health problems from smoking than survivors 
of non-tobacco-related cancers. If there are indeed differences in perceived severity of health 
problems from smoking between the two groups of survivors, then this is a construct that might 
help to inform cessation intervention efforts with cancer survivors, particularly for survivors of 
non-tobacco-related cancers, which is a group that tends to quit at lower rates. Further, if 
survivors of tobacco-related cancers have higher perceived severity of smoking than survivors of 
non-tobacco-related cancers, it is possible that this difference is particularly pronounced 
immediately following diagnosis when health and mortality are most salient. Researchers have 
argued that the time directly after diagnosis can serve as a “teachable moment” to cancer 
survivors who are likely most motivated to quit at this time.94,107,110,111 As time goes on after 
diagnosis, those who survive and continue to smoke might perceive fewer risks about smoking if 
they continue to survive and not develop comorbidities years after their diagnosis while 
continuing to smoke. Thus, if the difference in perceived severity between the two groups of 
survivors is small several years after diagnosis, then it would be crucial to target survivors of 
non-tobacco related cancers very early on in the cancer continuum when their perceived severity 
is significantly lower than that of survivors of tobacco-related cancers.  
In the current study, we explore differences in perceived severity of health problems from 
smoking between survivors of tobacco and non-tobacco-related cancers in a large national 
sample that includes survivors of various cancer types. To identify the optimal time to provide 
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smoking cessation interventions to each group, we also test if this relationship significantly 
differs as a function of time since diagnosis. We hypothesize:  
1.) Survivors of tobacco-related cancers will report greater perceived severity of health 
problems caused by smoking than survivors of non-tobacco-related cancers;  
2.) The difference in perceived severity of health problems from smoking between 
survivors of tobacco-related and non-tobacco-related cancer will be largest in survivors who 
have been diagnosed within two years. For those cancer survivors who experience survival 
beyond the initial active treatment phase (>2 years from diagnosis), both groups will have similar 
low levels of perceived severity. 
Methods  
Data Source and Samples  
 
We tested our hypotheses using data from Wave 1 of the Population Assessment of 
Tobacco Health (PATH) study, a U.S. national longitudinal survey of tobacco users and non-
users, funded by the National Institute of Health’s National Institute on Drug Abuse, and through 
the Food and Drug Administration (FDA) Center for Tobacco Products.112 Data were collected 
between 2013-2014 by audio computer-assisted self-interviewing (ACASI) and computer-
assisted personal interviewing (CAPI) questionnaires. The PATH study over-sampled tobacco 
users, young adults aged 18-24, and African Americans and used a stratified probability 
sampling design of 156 geographical primary sampling units (PSUs) with a final sample of 
32,320 adults 18 years and older. The PATH sample includes 433 cancer survivors who currently 
smoke every day or some days; we had complete data for our analyses for 409 (95%) of those 
survivors, which we used as our primary analytic dataset. The Institutional Review Board at the 
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University of North Carolina at Chapel Hill exempted the secondary analyses of PATH data as 
not human subjects research.   
Measures  
Diagnosis of Tobacco-Related Cancer:  
Type of cancer diagnosis was recorded through self-report in Wave 1. We created a 
dichotomous tobacco-related cancer variable based on the type(s) of cancer the participants 
reported having, using the classifications in the International Agency for Research on Cancer 
(IARC) guidelines 103, which has been used in previous studies.17,47,49 IARC guidelines consider 
tobacco-related cancers to include the following cancers: bladder, cervix, colon, esophagus, 
kidney, larynx/windpipe, liver, lung, mouth/tongue/lip, pancreas, stomach, throat, and uterus. We 
classified non-tobacco-related cancers as cancers of the blood, brain, breast, gallbladder, nervous 
system, prostate, rectum, ovary, soft tissue (muscle or fat), testis, thyroid, and 
lymphoma/Hodgkin disease and melanoma. Survivors of non-melanoma skin or “other” cancers 
were not included in these analyses because they are not generally included in studies of cancer 
survivors.  
Perceived severity of health problems.  
Perceived severity of health problems from smoking was assessed with two items, both 
rated on four-point scales: “To what extent, if at all, has using tobacco products damaged your 
health?” (rated from “not at all” to “a lot”) and “To what extent, if at all, are you worried that 
using tobacco products will damage your health in the future?” (rated from “not at all worried” to 
“very worried”). Scores were averaged to create a composite score that ranges from 1-4, with 




Length of time since diagnosis.  
Survivors in the PATH study reported their current age as well as their age at the time of 
their diagnosis. Time since diagnosis was created by subtracting current age from age at 
diagnosis. Responses were dichotomized into: 1) diagnosed within two years and 2) diagnosed 
over two years ago. We chose the cut-off of two years after diagnosis because most primary 
treatments of cancer are likely completed within this time frame. The time after two years from 
diagnosis likely marks a reduced frequency in regular interactions with oncology clinicians.  
Covariates.  
In addition to age in years, demographic variables included level of education (0=less 
than high school education and 1=high school education and above), race/ethnicity (1=non-
Hispanic White or 0=other race/ethnicity), and gender (0=female or 1=male) were included in 
the analyses as they have been previously shown to relate to smoking outcomes in the general 
population and in cancer survivors.11,35,47,49 
Analytic Strategy  
We first used logistic regression to confirm that previous associations between cancer 
type and cessation existed in the PATH data, using data from all survivors with a smoking 
history (n = 1,235). The focus of this study, however, was to examine differences in beliefs about 
the harms of smoking by cancer type among current smokers only. Using the primary sample 
described above, we examined the relationship between diagnosis of tobacco-related cancer and 
perceived severity of health problems from smoking using linear regression. In Model 1, we 
examined whether a diagnosis of tobacco-related cancer, controlling for age, race, education, 
sex, and length of time since diagnosis was significantly related to perceived severity of health 
problems from smoking. In Model 2, we added the interaction term of cancer diagnosis type × 
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length of time since diagnosis. We used SAS version 9.3 to conduct all analyses, which were 
two-tailed with a critical alpha of .05. We incorporated survey weights provided by the creators 
of the PATH data in all analyses, to compensate for variable probabilities of selection, 
differential nonresponse rates, and possible deficiencies in the sampling frame (e.g., under 
coverage of certain population groups).  
Results 
Table 1 describes characteristics of the sample in our study. A majority of survivors were 
diagnosed with non-tobacco-related cancers (58.1%), were diagnosed more than two years prior 
to survey (80.5%), and were female (64.3%), non-Hispanic White (82.5%), with at least a high 
school education (69.4%). The mean age of the sample was 54 (SE = 0.7). The mean perceived 
severity of health problems was 2.6 (SE = 0.1). In χ2 analyses, there was a significant difference 
between the two groups of survivors in education (p < .001): there was a higher percentage of 
less than high school-educated participants in the sample of survivors of tobacco-related cancers 
compared to survivors of non-tobacco-related cancers (37.7% versus 25.5%, respectively). There 
were no other significant differences in characteristics between the two groups.  
As in past studies of quit rates between the two groups of survivors, PATH survivors of 
tobacco-related cancer were significantly more likely to quit smoking after diagnosis (14.3% 
quit) than survivors of non-tobacco-related cancer (11.9% quit), after controlling for race, 
education, gender, and age (OR: 2.44; 95% CI: 1.49-3.99; p<.0001, results not shown). 
Table 2 displays the results from the linear regression model that tested the relationship 
between diagnosis of tobacco-related cancer and perceived severity of health problems from 
smoking. Our main effect hypothesis (Model 1) was supported: those diagnosed with tobacco 
related cancers reported higher perceived severity of health problems from smoking compared to 
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those diagnosed with non-tobacco-related cancers (β = .25; 95% CI: .01-.49; p = .04). Contrary 
to our interaction hypothesis, the relationship between tobacco-related cancer diagnosis and 
perceived severity of health problems from smoking did not vary by length of time since 
diagnosis (interaction term β = .09; 95% CI: -.06-.52; p = .76). In other words, the relationship 
between diagnosis of tobacco-related cancer and perceived severity was the same for recently 
diagnosed and for long-term survivors (Model 2).  
 Discussion 
 Our study found that survivors of tobacco-related cancer reported higher perceived 
severity of health problems from smoking than survivors of non-tobacco-related cancer and that 
this relationship was the same for short-term and long-term survivors. This finding highlights: 1) 
that the belief about the harms of smoking is a potentially important factor that could explain 
why survivors of tobacco-related cancer quit at higher rates than survivors of non-tobacco-
related cancer and 2) that there might not be just one “teachable moment” in changing beliefs 
about the harms of smoking because differences in perceived severity between the two groups 
persisted for years after diagnosis. Clinicians who continue to discuss the harms of tobacco use 
after cancer diagnosis throughout ongoing care (e.g., through motivational interviewing 
techniques)— particularly with their patients with non-tobacco-related cancers, could contribute 
to increased intentions to quit, and ultimately smoking cessation among some patients. Future 
research with longitudinal data with multiple assessments of perceived severity and smoking 
status over time should investigate the extent that the perceived severity of the harms of smoking 
mediates the relationship between diagnosis of tobacco-related cancer and smoking cessation.  
One potential explanation for differences in beliefs by cancer type that we observed is 
that survivors of tobacco-related cancer receive more provider advice to quit and social pressure 
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from friends and family, each of which might alter beliefs about the dangers of continued 
smoking. Future research should explore the role of provider and social network actions in 
producing health-related beliefs. It would also be worthwhile to examine whether there are 
differences between the two groups of survivors in other smoking-related beliefs (e.g., attitudes 
about quitting smoking) to identify additional potential targets for cessation interventions.  
Differences in beliefs may not account for all of the observed differences in successful 
cessation by cancer type. Survivors of tobacco-related cancers might be using more efficacious 
cessation strategies (e.g., combined behavioral counseling and pharmacological treatment) than 
survivors of non-tobacco-related cancer based on recommendations from their clinicians. More 
research is warranted to explore other potential influences of cessation such as type of cessation 
strategies used between the two groups of survivors. 
This study exhibits several strengths. Data come from a large national U.S. survey that 
were weighted to adjust for the complex sampling design. The samples of survivors in this study 
include a wide range of cancer types, which might be more representative of the cancer survivor 
population than studies of survivors of fewer cancer types. Last, this data included information 
on when survivors were diagnosed, which allowed for us to examine how relationships between 
cancer diagnosis and perceived severity of smoking varied over time.  
There are two main limitations of the current study. First, type of cancer diagnosis was 
self-reported, which might not be as accurate as a cancer diagnosis that is confirmed by medical 
records. Another study, however, used medical records to confirm cancer diagnosis and found a 
strong correlation—more than 95%— between self-reported diagnosis and medical record-
confirmed diagnosis.49 Second, there were only 80 survivors diagnosed within two years in this 
sample. Larger studies with more variability in length of time since diagnosis are needed to 
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ascertain if there are greater differences in perceived risks of smoking between survivors of 
tobacco and non-tobacco-related cancers in the time shortly after cancer treatment compared to 
several years after diagnosis.  
Conclusions and Implications 
In this study, we found differences in perceived severity of health problems from 
smoking between survivors of tobacco-related and non-tobacco-related cancers that persist years 
after diagnosis. These findings could potentially in part explain differences in quit rates between 
the two groups. Longitudinal data are needed to assess whether the perceived severity of health 
problems from smoking mediates the relationship between diagnosis of tobacco-related cancer 
and quitting. Additionally, randomized control trials of smoking cessation interventions are 
needed to test if changing beliefs about the harms of smoking—particularly among survivors of 
non-tobacco-related cancers—in turn produces higher quit rates. This research underscores the 
importance of integrating smoking cessation programs into oncology care throughout the 
survivorship continuum—from diagnosis to long-term follow-up care—and for all smokers, 
regardless of cancer type. We recommend that clinicians continually assess and discuss beliefs 
about the harms of continued smoking in survivors of all cancer types and refer patients to 
evidence-based smoking cessation resources. This approach could particularly benefit survivors 
of non-tobacco-related cancers—who might not believe smoking is as harmful to their health as 




Table 4.1: Characteristics of the PATH Sample  






















Percentages, Notes: Means, and standard deviations are weighted.  
* Indicates p < .001 in chi-square or bivariate regression analyses. 
  




Characteristic   n  %/Mean/SE   n %/Mean/SE   n %/Mean/SE 
Cancer Type 
   Tobacco-related 
   Non-tobacco-related 
 
174                                         

















   Female  
   Male 
 
278                  

















   Non-Hispanic White 
   Non-Hispanic Black 
   Hispanic 
   Other 
 
327                             
  34                               
  25                               
  23                               
 
82.5 
  8.3 
  5.5 
  3.8 
 
140 
    9 
  12 
  13 
 
83.3 
  5.2 
  7.2 
  4.2 
 
187 
  25 
  13 




  4.2 
  3.4 
Completed Education 
   Less than HS 
   HS graduate 
   Some college 
   College degree or more 
 
128                              
  84                              
153                              







  61 
  27 
  74 





  5.8 
 
  67 
  57 
  79 






Time since diagnosis 
   ≤ 2 years 
   > 2 years 
 
  80                              
















Age 409                              54.0 (0.7) 174 53.0 (1.5) 235 54.8 (0.9) 
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Table 4.2: Linear Regression Analyses  
(n = 409 cancer survivors who currently smoke) 
 
   n 
 
Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Diagnosis of tobacco-related cancer 
    Non-tobacco-related (ref) 
    Tobacco-related 
Race 
    Other (ref) 
    Non-Hispanic White  
Education 
   Less than HS (ref) 
   HS graduate 
Sex 
   Female (ref) 
   Male 
Age 
Time since diagnosis 
   > 2 years (ref) 
   ≤ 2 years 
 
Diagnosis of tobacco-related cancer 
(no or yes) × Time since diagnosis  





















   .25 (.01-.49)* 
 
— 
   .20 (-.07-.47) 
 
— 
  -.13 (-.35-.09) 
 
— 
  -.01 (-.23-.20) 
   .01 (.01-.02)* 
 
— 
   .09 (-.20-0.38) 
 
— 
 .23 (-.06-.52) 
 
— 







 .01 (.01-.02)* 
  
 — 
 .05 (-.37-.47) 
  
.09 (-.49-.68) 
Notes: * p < 0.05 
Model 1: Effect of diagnosis of tobacco-related cancer on perceived severity of health problems from smoking, 
controlling for age, race, sex, education, and time since diagnosis. 
Model 2: Effect of diagnosis of tobacco-related cancer on perceived severity of health problems from smoking, 
controlling for age, race, sex, and education, time since diagnosis, and the interaction term (Diagnosis of tobacco-







CHAPTER 5: MANUSCRIPT 3-  
DUAL CIGARETTE AND E-CIGARETTE USE IN CANCER SURVIVORS:  




Introduction. Cancer survivors who smoke cigarettes face multiple health risks from 
continued smoking and may be particularly motivated to quit. Some smokers use e-cigarettes as 
a strategy to reduce or quit combustible cigarette use, but research on whether cancer survivors 
do the same is limited. Research is needed to understand whether cancer survivors use e-
cigarettes at higher rates than smokers never diagnosed with cancer, to inform provider-patient 
discussions about e-cigarettes. Methods. Using data from current cigarette smokers in the 
Population Assessment of Tobacco Health (PATH) study, we examined differences in e-cigarette 
use and reasons for use among cigarette smokers between cancer survivors (n = 433) and those 
without a prior cancer diagnosis (n = 10,872). Results. Among smokers, nearly 6 in 10 of both 
cancer survivors and those without a cancer diagnosis have ever used e-cigarettes, and nearly one 
quarter of both groups currently use e-cigarettes. Results suggest that cancer survivors might be 
more likely to be ever (OR = 1.28; p=.05) or current (OR = 1.25; p=.06) e-cigarette users 
compared to those never diagnosed, although these results were marginally significant. The 
majority of both groups (>71%) reported using e-cigarettes for perceived health-related 
reasons—including smoking reduction. Conclusions. Our study found that among smokers, 
cancer survivors are using e-cigarettes at similar rates as never-diagnosed smokers and both 
groups use e-cigarettes largely for perceived health-related reasons. Clinicians may need to 
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routinely ask their patients who smoke about e-cigarette use and address the limited research on 
the efficacy of e-cigarettes as a cessation aid as compared to other evidence-based options. 
Introduction 
 The smoking prevalence among cancer survivors ranges widely by cancer type from 7% 
to 51%.1,7-10 Smoking rates are especially high in survivors of tobacco-related cancers (e.g., 
cervical,1,11-13 bladder,13 and lung cancer13). Researchers estimate that 14% to 64% of cancer 
survivors who smoked prior to their cancer diagnosis continue to smoke after their 
diagnosis.7,10,47,84 Quitting smoking is beneficial for the health of any smoker, but cancer 
survivors have an even more urgent need to quit because continued smoking after a cancer 
diagnosis is associated with lower survival,2,4  higher rates of recurrent disease,5 more primary 
tumors,19-23 decreased efficacy of cancer treatment,3 and increased treatment-related 
complications and symptom burden.6,24,25 Cancer survivors who smoke, as compared to smokers 
without cancer, are particularly motivated to quit smoking.39  
Smokers in the general population often perceive and use e-cigarettes (also known as 
electronic cigarettes or electronic nicotine delivery systems—ENDS) as a strategy to reduce or 
eliminate combustible cigarette use.52-54 Research on whether cancer survivors do the same is 
limited. One study found that 34.3% of cancer survivors who were current conventional cigarette 
smokers had ever used e-cigarettes, but this study did not compare e-cigarette use rates among 
current smokers to a population never diagnosed with cancer.113 Kruse and colleagues analyzed 
e-cigarette use among adults with and without comorbidities in a large national sample in 2014 
and 2015 and found that among current smokers, ever and current e-cigarette use were not 
different between cancer survivors and the population without any medical comorbidities.62 This 
study, however, did not examine differences in use by type of cancer, or account for 
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demographic characteristics like age.62 The majority (87%) of cancer survivors in the U.S. are 
diagnosed at or over age 50,63 whereas younger age is associated with higher e-cigarette ever 
use.64,65 Thus, it might be important to account for differences in age to determine whether 
survivors are using e-cigarettes at rates beyond what we would expect for their age group.   
Few studies have examined e-cigarette use by cancer type. A cross-sectional survey of 
head and neck cancer patients who were current or former smokers found that 21.7% of patients 
reported using e-cigarettes as a method to quit smoking.114 A longitudinal study of currently 
smoking cancer patients found that a high percentage of thoracic and head and neck cancer 
patients were e-cigarette users (36.2% compared to 26.5% of survivors of all cancer types), 
which suggests that e-cigarette use might vary by cancer type.115 Survivors of tobacco-related 
cancers might be more motivated to quit smoking combustible cigarettes because of the well-
known association between smoking and tobacco-related cancers (e.g., lung cancer). If e-
cigarette use rates are relatively high for cancer survivors, and particularly for survivors of 
specific tobacco-related cancers, then clinicians who treat cancer survivors may need to discuss 
the current evidence about the cessation efficacy and harms of e-cigarettes with their patients 
who are trying to quit or reduce smoking.  
Although smokers of combustible cigarettes who also use e-cigarettes (i.e., “dual users”) 
often perceive that e-cigarettes help people quit and report using e-cigarettes to attempt to quit or 
reduce smoking cigarettes,56,116 the evidence in support of e-cigarettes as a successful smoking 
cessation strategy is modest and controversial. Two meta-analyses that pooled the results of 
cohort, cross-sectional, and randomized control trials reported that e-cigarette use was associated 
with significantly lower odds of quitting smoking combustible cigarettes.55,56 Studies included in 
these meta-analyses, however, have been criticized as being limited by selection bias, low 
 
 60 
reliability, and confounders.117 In contrast, two other meta-analyses—including a Cochrane 
review, which included only randomized control studies, found that e-cigarette users were more 
likely to quit conventional cigarettes if their e-cigarettes contained nicotine versus if they did not 
contain nicotine.57,58 There is one published randomized control trial that compared e-cigarettes 
to another other smoking cessation method—nicotine replacement therapy (NRT), but there were 
no significant differences in quit rates between the intervention arms59 and this trial had 
significant methodological limitations.56 In a systematic review of the literature on e-cigarettes 
and smoking cessation, Malas and colleagues point out that it is unclear whether e-cigarettes 
only help certain types of smokers reduce or quit cigarette use, and if their efficacy changes with 
the use of other cessation aids such as counseling or NRT.117 Thus, as the literature currently 
stands, the evidence is inconclusive that e-cigarettes help smokers—including both cancer 
survivors and those never diagnosed—quit combustible cigarettes. The authors of three 
systematic reviews of smoking cessation interventions for cancer survivors recommend that 
cancer survivors receive the gold standard for smoking cessation treatment in the general 
population: a combination of FDA-approved medication—mainly nicotine replacement therapy 
and varenicline— and behavioral therapies such as counseling and reading materials.37-39 
In addition to the limited research on the efficacy of e-cigarettes as a smoking cessation 
tool, there are known short-term harms of e-cigarette use, although more research is needed to 
document long-term health consequences of using e-cigarettes specifically in cancer survivors. 
Meernik and Goldstein argue that clinicians should not recommend e-cigarettes to their patients 
who are trying to quit smoking because of safety concerns (e.g., burns and other injuries) and 
clinicians’ ethical framework to do no harm.60 The potential interactions of e-cigarettes and 
cancer therapies are also unknown.61 E-cigarettes are thought to be less toxic than conventional 
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cigarettes, but they still contain hazardous chemicals that could increase a smoker’s risk for 
disease, and the long-term health risk of e-cigarettes is currently unknown,118 particularly among 
cancer survivors who are already at higher risk for developing cancer than the general 
population.119 It is currently unclear if the benefits of e-cigarettes as a smoking cessation tool 
outweigh the potential harms in cancer survivors.    
 There are several gaps in the literature on patterns of e-cigarette use and reasons for use 
in cancer survivors who smoke combustible cigarettes as they compare to smokers never 
diagnosed with cancer. It is possible that cancer survivors, who may be more motivated to quit 
smoking than smokers without a prior cancer diagnosis,39 are more likely to report using e-
cigarettes for health-related reasons (e.g., to cut back on smoking). In the current study, we used 
national data to examine two research questions: 1) Does the prevalence of e-cigarette use among 
current combustible cigarette smokers vary by cancer survivorship status and cancer type?; and 
2) Do reasons for e-cigarette use among smokers vary by cancer survivorship status?  
Methods  
Data Source and Sample  
We used data from Wave 1 of the Population Assessment of Tobacco Health (PATH) 
study, funded by the National Institutes of Health, through the National Institute on Drug Abuse, 
and the Food and Drug Administration (FDA).112 The PATH study is a national longitudinal 
survey on tobacco use behavior that sampled tobacco users and non-users in the U.S (N = 32,320 
adults). The PATH study over-sampled tobacco users, young adults aged 18-24, and African 
Americans. The PATH methodology is described elsewhere.112 The analytic sample used to 
assess differences in e-cigarette use by cancer survivorship status consisted of all adult (age 18 
and above) current conventional cigarette smokers who reported their cancer survivorship status 
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(n=11,305). The analytic sample used to compare e-cigarette use by cancer type consisted of 433 
cancer survivors who currently smoked conventional cigarettes. The analytic sample used to 
assess differences in reasons for e-cigarette use by cancer survivorship status consisted of all 
current e-cigarette users who reported reasons for use (n = 2,510). Data were collected between 
2013-2014 by audio computer-assisted self-interviewing (ACASI) and computer-assisted 
personal interviewing (CAPI) questionnaires. The Institutional Review Board at the University 
of North Carolina at Chapel Hill exempted the secondary analyses of PATH data as not human 
subject research.   
Measures  
Cancer Survivorship Status. A dichotomous cancer survivorship status variable was 
defined based on participant response to the question “Have you ever been told by a doctor or 
other health professional that you had cancer?” with “yes” responses categorized as cancer 
survivors.  
Diagnosis of Tobacco-Related Cancer. To assess variation in e-cigarette use by cancer 
type, we derived a dichotomous indicator of whether a cancer survivor was diagnosed with a 
cancer that was tobacco-related or not tobacco-related from the PATH questions about cancer 
diagnosis. Participants who indicated having a cancer diagnosis were asked, “What kind of 
cancer?” We classified cancers that are tobacco-related using the 2009 International Agency for 
Research on Cancer (IARC) guidelines on cancers related to tobacco use,103 as has been done in 
previous studies.17,47,49 Tobacco-related cancers are cancers of the bladder, cervix, colon, 
esophagus, kidney, larynx/windpipe, liver, lung, mouth/tongue/lip, pancreas, stomach, throat, 
and uterus; all other types were considered non-tobacco related. Non-melanoma skin cancer and 
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“other cancer” responses were not included in these analyses because these cancers are not 
typically included in studies that assess cigarette use in cancer survivors.  
Cigarette Use. All participants were asked whether they smoked at least 100 cigarettes in 
their life. Those who indicated they had were further asked whether they currently smoke 
cigarettes "every day," "some days," or "not at all." Current smokers were characterized as those 
who smoked at least 100 cigarettes in their lifetime and currently smoked every day or some 
days.  
E-cigarette Use. We constructed two measures of e-cigarette use: ever use and current 
use. After a brief introduction to e-cigarettes, PATH participants were asked, “Have you ever 
used an e-cigarette, such as NJOY, Blu, or Smoking Everywhere, even one or two times?” 
Participants were categorized as ever users of e-cigarettes or never-users of e-cigarettes. Ever 
users of e-cigarettes were also asked, “Do you now use e-cigarettes…Every day, Some days, or 
Not at all.” Those who responded “Every day or some days” were considered current users. 
Participants were also asked, “How old were you when you first started using an e-cigarette, 
even one or two times?” and provided their age in years. We created a dichotomous variable to 
determine whether cancer survivors started using e-cigarettes before they were diagnosed or after 
diagnosis by subtracting their age at first e-cigarette from their age at diagnosis. Cancer survivors 
who first used e-cigarettes the year they were diagnosed were coded as having first used e-
cigarettes after diagnosis.  
Reasons for E-cigarette Use. Participants who reported currently using e-cigarettes were 
asked a series of yes or no questions about 13 reasons they use e-cigarettes. Four questions were 
related to health. These health-related reasons include: “they might be less harmful than 
cigarettes,” “they can help people to quit smoking,” “they might be less harmful to others than 
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cigarettes,” and “they can be a way of cutting down on cigarette smoking.” Participants answered 
nine questions about e-cigarette use that were unrelated to health (e.g., “they came in flavors I 
liked”, “it feels like smoking a regular cigarette,” “I could use e-cigarettes at times when or in 
places where smoking cigarettes wasn’t allowed,” “People who are important to me use e-
cigarettes.”) We analyzed each of the 13 reasons separately.  
Additional Variables: In some analyses we included as covariates measures of age (in 
years), race/ethnicity (1=non-Hispanic White or 0=other race/ethnicity), education (0=less than 
high school education and 1=high school education and above), and gender (0=female or 
1=male) because these variables are related to e-cigarette use in the general population64,65 and in 
cancer survivors.113 
Analytic Strategy  
We calculated descriptive statistics for all outcome variables. We used SAS version 9.3 
to conduct all analyses, using the PATH survey weights to compensate for variable probabilities 
of selection, differential nonresponse rates, and possible deficiencies in the sampling frame (e.g., 
the under coverage of certain population groups). We examined the extent and pattern of missing 
data for all covariate variable measures. No variables were missing at a rate higher than 5%; 
cases with data missing on predictor or control variables were dropped in logistic regression 
tests. 
Prevalence of e-cigarette use: We conducted logistic regression analyses to examine 
differences in e-cigarette ever use and current use between cancer survivors and those without a 
cancer history, controlling for age, income, race, and education; we had complete information for 
n = 10,548 participants. Given the smaller sample of e-cigarette users with a cancer diagnosis, 
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we relied on chi-square analyses to examine differences in e-cigarette use between survivors of 
tobacco-related and non-tobacco-related cancers.  
Reasons for e-cigarette use: We conducted chi-square analyses to examine whether there 
were significant differences in reasons for e-cigarette use as a function of cancer survivorship 
status.  
Results  
 Table 1 describes characteristics of the 11,305 PATH participants who were current 
combustible cigarette smokers, stratified by cancer status. Cancer survivors, as compared to 
those without a prior diagnosis of cancer, were significantly more likely to be female (64.5% vs. 
43.7%), non-Hispanic White (82.4% vs. 69.1%, respectively), have a less than high school 
education (31.5% vs. 26.4%), and were older (mean age 54.2 years vs. 41.1 years).  
 Ever E-cigarette Use.  
Among current smokers, 59.4% of cancer survivors reported ever using an e-cigarette 
compared to 63.2% of those never diagnosed with cancer (Table 1). In logistic regression 
analyses controlling for race, education, sex, and age (Table 2), cancer survivors had 1.28 times 
the odds of ever using e-cigarettes compared to those without a history of cancer (OR = 1.28; 
95% CI: 1.01-1.63; p=.0457). In this sample, 90% of cancer survivors who ever used e-cigarettes 
first tried them during the year of diagnosis or sometime after diagnosis.  
There were no significant differences in ever e-cigarette use between survivors of 
tobacco-related cancers and those diagnosed with non-tobacco-related cancers (62.5% versus 





Current E-cigarette Use.  
 Among cancer survivors who were current smokers, 23.1% reported currently using e-
cigarettes every day or some days compared to 22.3% of those who have never been diagnosed 
with cancer (Table 1). In adjusted logistic regression analyses (Table 2), cancer survivors had 
1.25 times the odds of currently using e-cigarettes compared to those without a history of cancer, 
but this association was marginal (OR = 1.25; 95% CI: 0.99-1.58; p=.06).  
Rates of current e-cigarette use between those diagnosed with tobacco-related cancers 
and those diagnosed with non-tobacco-related cancers (23.8% versus 22.6%) did not differ 
significantly (χ2= 0.08; p=.78; results not reported in Table 2).  
 Reasons for E-cigarette Use.  
 Table 3 displays the reasons why current e-cigarette users who smoke reported using e-
cigarettes in cancer survivors and in the general population without a cancer history. The 
majority of both cancer survivors (ranging from 75%-88%) and those without a prior cancer 
diagnosis (ranging from 72%-85%) reported using e-cigarettes for health-related reasons (e.g., 
“they might be less harmful to people around me than cigarettes.”) Similarly, the majority of 
both cancer survivors and those never diagnosed with cancer endorsed using e-cigarettes because 
they could use them at times when or in places where smoking cigarettes was not allowed 
(>83%) and because e-cigarettes do not smell (>76%). Most cancer survivors and those without a 
history of cancer who currently use e-cigarettes did not report using e-cigarettes because people 
in the media or other public figures use e-cigarettes, because people who are important to them 
use e-cigarettes, or because the advertising of e-cigarettes appeals to them. In chi-square analyses 
for each reason for using e-cigarettes, contrary to our expectation, cancer survivors were not 
more likely to report using e-cigarettes for health-related reasons than smokers without a prior 
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cancer diagnosis. We found significantly more people never diagnosed with cancer selected 
“people who are important to me use e-cigarettes” as a reason for using e-cigarettes compared to 
cancer survivors (χ2= 5.16; p=.02), although this significant p-value could have been detected by 
chance.  
Discussion  
This national study found that nearly 6 in 10 cancer survivors who smoke have also used 
e-cigarettes, and nearly one quarter of survivors are currently doing so, regardless of cancer type. 
These rates were similar to those without a prior cancer diagnosis. In this sample, 90% of cancer 
survivors who ever used e-cigarettes first tried them during the year of diagnosis or after they 
were diagnosed and more than 75% of the cancer survivors who reported dual use of cigarettes 
and e-cigarettes cited health-related reasons for their e-cigarette use, including smoking 
reduction or cessation. This suggests that a substantial number of smokers may try e-cigarettes as 
a cessation strategy following a cancer diagnosis. 
Similar to the study by Kruse et al.,62 we observed no differences in e-cigarette use 
prevalence of cancer survivors when compared to non-cancer survivors, although once we 
adjusted for age, race/ethnicity, education, and gender, cancer survivors were more likely to ever 
use e-cigarettes and marginally more likely to currently use e-cigarettes. Larger samples are 
needed to confirm whether there might be a difference in e-cigarette use between cancer 
survivors and a population without a prior cancer diagnosis, adjusting for age, education, 
race/ethnicity, and gender.  
We also found that cancer survivors report currently using e-cigarettes for the same 
reasons as the general population. The majority of dual current e-cigarette and combustible 
cigarette users indicated they use e-cigarettes because they might be less harmful to themselves 
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or others, could be used at times when smoking cigarettes was not allowed, they do not smell, or 
could help people quit smoking. It does not appear that experiencing a cancer diagnosis 
motivates people to use e-cigarettes for health-related reasons more so than those never 
diagnosed with cancer because the majority (more than 72%) of both groups report that they use 
e-cigarettes for health-related reasons, although larger studies are needed to better understand 
this relationship.  
Clinicians who treat cancer patients who smoke, regardless of cancer type, may therefore 
want to discuss the current evidence about the cessation efficacy and harms of e-cigarettes, along 
with evidence-based cessation methods such as pharmacotherapy (e.g., NRT, varenicline, 
bupropion) and behavioral counseling (e.g., skills training, stress management),10,39 when asking 
their patients about their cessation efforts. By discussing that the efficacy and harms of e-
cigarettes use in smoking cessation are currently unknown, clinicians may help change patient 
perceptions that e-cigarettes will help them quit or reduce smoking, and encourage techniques for 
which the evidence base is stronger. It may be important for clinicians to have these discussions 
with their patients who smoke throughout primary care, even before patients are diagnosed with 
cancer because both cancer survivors and those without a cancer history cited health-related 
reasons for using e-cigarettes. Thus, it might be worthwhile for clinicians to follow the emerging 
literature about the cessation efficacy and harms of e-cigarettes to best advise their patients about 
the most effective cessation options. 
There are several strengths to this study. Data come from a large national U.S. survey that 
were weighted to adjust for the complex sampling design. These data include information on 
cancer diagnosis, which allows for comparison of e-cigarette use and reasons for use between 
survivors and those never diagnosed with cancer. The data also include an assessment of current 
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e-cigarette use, which might better describe the extent that cancer survivors who smoke are using 
e-cigarettes as a smoking cessation tool than if the data only contained information about ever 
use, where it would have been difficult to differentiate between those who only used e-cigarettes 
experimentally from those who use more frequently.    
There are several limitations of this study that are important to keep in mind. First, the 
number of cancer survivors who reported currently using e-cigarettes was small (n = 99) and 
results should be interpreted with caution because they might not generalize to all cancer 
survivors who are dual users of e-cigarettes and cigarettes. This sample size precluded us from 
controlling for demographic characteristics when analyzing differences in reasons for using e-
cigarettes. The samples of current e-cigarette users who were cancer survivors and those never 
diagnosed, however, were not significantly different in age or education—two factors related to 
e-cigarette use.64,65 The limited sample size might also contribute to non-significant differences 
in e-cigarette use between survivors of tobacco-related and non-tobacco-related cancers. Larger 
studies of e-cigarette use and reasons for use in cancer survivors are needed, with a focus on 
differences between survivors of various cancer types. Second, cancer diagnosis in this study 
was self-reported, which might not be as accurate as a diagnosis confirmed by medical records. 
Another study, however, used medical records to confirm cancer diagnosis and found a strong 
correlation—more than 95%— between self-reported diagnosis and medical record-confirmed 
diagnosis.49  
Conclusions and Implications 
Our results indicate that cancer survivors using e-cigarettes at similar rates as those 
without a cancer history. Many current cigarette smokers—regardless of whether they have been 
diagnosed with cancer or not—are using e-cigarettes because they perceive that e-cigarettes will 
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help them quit smoking cigarettes or reduce their cigarette consumption. Oncology clinicians 
should recognize that up to a quarter of their patients who smoke might be currently using e-
cigarettes as a perceived harm reduction tool. It would be worthwhile for clinicians who treat 
cancer survivors to stay abreast of research related to the efficacy and harms of e-cigarettes as a 
smoking cessation tool and to discuss any misconceptions about e-cigarettes with their patients 









 n = 433 
   No Cancer 
   n = 10,872 
  Total 
   n = 11,305 
 
Characteristic   n     %/Mean (SE)     n %/Mean (SE)     n %/Mean (SE) p-valueb 
Sex 
   Female  





   64.5 
   35.5 
 
  5,064 
  5,804 
 
  43.7 
  56.3 
 
  5,360 
  5,941 
 
  44.6 





   Non-Hispanic White 
   Non-Hispanic Black 
   Hispanic 
   Other 
 
336 
  35 
  26 
  24 
 
   82.4 
     8.4 
     5.4 
     3.7 
 
  7,059 
  1,421 
  1,420 
     804 
 
  69.1 
  13.2 
  11.6 
    6.1 
 
  7,395 
  1,456 
  1,446 
     828 
 
  69.7 
  13.0 
  11.3 





   Less than HS 
   HS graduate 
   Some college 
   College degree or more 
 
138                             
  87                             
160                             







  3,023 
  2,768 
  3,873 
  1,145 
 
  26.4 
  28.1 
  33.6 
  11.2 
 
  3,161 
  2,855 
  4,033 
  1,190 
 
  26.6 
  28.0 
  33.6 
  10.3 
      
      .02 
Age 
 
Ever E-cigarette Userc 
    Tobacco-related 
    Non-tobacco-related 
Current E-cigarette User 
    Tobacco-related 
    Non-tobacco-related 
433   
 
250   
108  
142 
  99  
  44 
  55                       
    54.2 (0.7) 
 
    59.4 
    62.5 
    57.4 
    23.1 
    23.8 
22.6
10,871 
   
  6,791 
     -- 
     -- 
  2,411 
     -- 
     -- 
  41.1 (0.2) 
 
  63.2 
     -- 
     -- 
  22.3 
     -- 
     -- 
11,304 
   
  7,041 
     -- 
     -- 
  2,510 
     -- 
     -- 
  41.7 (0.2) 
 
  63.1 
    -- 
    -- 
  22.3 
    -- 
    -- 
      .01 
     
      .16 
 
 
      .70 
Notes: Means and percentages are weighted.  
a58.2% of cancer survivors were diagnosed with non-tobacco-related cancers. 
bp values from Rao-Scott chi-square test or bivariate linear regression analyses. 





Table 5.2: Logistic Regression Analyses 
n = 10,548 
  Ever E-cigarette Use Current E-cigarette Use 
 n OR (95% CI) p-value OR (95% CI) p-value 
Cancer Diagnosis  
    No history of Cancer (ref) 
    Cancer Survivor 
Race 
    Other (ref) 
    Non-Hispanic White  
Education 
   Less than HS (ref) 
   HS graduate 
Sex 
   Female (ref) 
   Male 
 
Age  
  (Measured continuously) 
 
10,154 
     394 
  
  3,453 
  7,095 
   
  2,894 
  7,654 
   
  5,016 





 1.28 (1.01-1.63) 
 
— 
 1.62 (1.47-1.77) 
 
— 
 1.09 (0.98-1.22) 
 
— 







































  <.001 
 
 






Table 5.3: Reasons for current e-cigarette use  
n = 2,510 
 
   Cancer 
  n = 99 
  No Cancer 
    n = 2,411 
    Total 
   n = 2,510 
 
Reason for E-cigarette Use  n                         %    n  %   n % p-valuea 
Health-Related Reasons        
They might be less harmful to 
me than cigarettes 
 77 78.4 1,935 80.5 2,012 80.4 .64 
 
They might be less harmful to 
people around me than 
cigarettes 
 86 87.5 2,043 85.1 2,129 85.2 .52 
Using them help people to 
quit smoking 
 69 74.5 1,727 71.9 1,796 72.0 .52 
Used them as a way of 
cutting down on cigarette 
smoking 
 79 80.1 1,693 71.8 1,772 72.2 .11 
Non-Health-Related Reasons        
People in the media or other 
public figures use e-cigarettes 
 21 19.0    429 18.0   450 18.0 .83 
Could use e-cigarettes at 
times when or in places 
where smoking cigarettes 
wasn’t allowed 
 90 88.9 2,017 83.5 2,107 83.8 .33 
Came in flavors I liked  64 65.8 1,586 63.8 1,650 63.9 .72 
E-cigarettes don’t smell  78 81.2 1,827 76.1 1,905 76.3 .33 
Feels like smoking a regular 
cigarette 
 45 46.0 1,091 47.3 1,136 47.2 .79 
More acceptable to non-
tobacco users 
 66 68.1 1,698 70.7 1,764 70.6 .58 
People who are important to 
me use e-cigarettes 
 13 10.8    451 18.9    464 18.5 .02 
I like socializing while using 
an e-cigarettes 
 41 40.8    898 37.2    939 37.4 .50 
The advertising for e-
cigarettes appeals to me 
 14 12.6    469 19.4    483 19.1 .07 
Notes: Percentages are weighted.  





CHAPTER 6: SUMMARY AND DISCUSSION  
6.1 Summary of Research Findings 
The purpose of this dissertation was to better understand smoking-related factors 
uniquely influenced by receiving a cancer diagnosis that could be targeted in smoking cessation 
interventions to improve quit rates and ultimately reduce morbidity and mortality outcomes 
among cancer survivors. This dissertation examined psychosocial predictors of both smoking 
cessation and the length of time it took survivors to quit, diagnosis of a tobacco-related cancer as 
a correlate of perceived severity of health problems from smoking, and whether cancer survivors 
who smoke are using e-cigarettes—a perceived harm reduction strategy—to help them reduce or 
quit smoking. 
Manuscript 1: Psychosocial Factors and Quitting Smoking in Long-Term Cancer Survivors 
 In Manuscript 1, I hypothesized that survivors with higher psychological distress, lower 
HRQOL, and lower perceived social support at one year after diagnosis would be less likely to 
quit smoking within 10 years of diagnosis and would take longer to quit compared to those with 
lower psychological distress, higher HRQOL, and higher perceived social support. Of the four 
psychosocial variables that I examined in this sample, only physical HRQOL was significantly 
associated with smoking cessation and when cessation occurred. Cancer survivors with low 
physical HRQOL were both significantly less likely to quit smoking when controlling for cancer 
type and number of comorbid conditions and took several more years to quit than survivors with 
high physical HRQOL. The first noticeable increase in the probability of quitting occurred at 2 
 
 75 
years after diagnosis in survivors with high physical HRQOL compared to year 6 in survivors 
with low physical HRQOL. Survivors of tobacco-related cancer with high physical HRQOL 
were the most likely group to quit smoking, while survivors of tobacco-related cancer with low 
physical HRQOL were the least likely group to quit.   
Manuscript 2: Diagnosis of Tobacco-Related Cancer and Perceived Severity of Health Problems 
from Smoking 
 
 In Manuscript 2, I hypothesized that survivors of tobacco-related cancers would report 
greater perceived severity of health problems caused by smoking than survivors of non-tobacco-
related cancers and that the difference in perceived severity between the two groups would be 
largest in survivors who had been diagnosed within two years. In partial support of my 
hypotheses, I found that survivors of tobacco-related cancer reported higher perceived severity of 
health problems from smoking than survivors of non-tobacco-related cancer, but contrary to my 
expectation, this relationship was the same for survivors diagnosed within two years and for 
long-term survivors. 
Manuscript 3: Dual cigarette and e-cigarette use in cancer survivors  
 
In Manuscript 3, I examined whether the prevalence of e-cigarette use among current 
combustible cigarette smokers varied by cancer survivorship status and cancer type and whether 
reasons for e-cigarette use varied by cancer survivorship status. I found that nearly 6 in 10 cancer 
survivors who smoke have also used e-cigarettes, and nearly one quarter of survivors are 
currently doing so, regardless of cancer type. Prevalence rates of ever e-cigarette use and current 
e-cigarette use were similar in cancer survivors and those without a cancer history. Results 
suggest that cancer survivors might be even more likely to ever or currently use e-cigarettes 
compared to those without a prior cancer diagnosis, although associations in this sample were 
marginally significant. In this sample, cancer survivors reported currently using e-cigarettes for 
 
 76 
the same reasons as the general population; the majority of both groups (>71%) reported using e-
cigarettes for perceived health-related reasons—including smoking reduction. 
6.2 Strengths and Limitations  
 This dissertation possesses several strengths. First, both datasets used in these analyses 
(SCS-I and PATH) were large national datasets that included rich information on cancer 
survivors, including the type of cancers with which survivors were diagnosed and when they 
were diagnosed. These data are helpful for identifying populations that might need more 
intensive smoking cessation resources and ideal times to intervene. For example, Manuscript 1 
identified that survivors with low physical HRQOL—and particularly those diagnosed with 
tobacco-related cancers—were less likely to quit smoking and took longer to quit smoking 
among those who did quit than others, and thus might need to be targeted with intensive 
cessation resources that span several years after diagnosis to address their unique barriers to 
quitting. Manuscript 2 found that survivors of non-tobacco-related cancer—both those recently 
diagnosed and longer-term survivors— had lower perceived severity of health problems from 
smoking, which indicates that clinicians should work to increase the perceived harm of smoking 
in those survivors throughout the cancer continuum.  
Second, the longitudinal nature of the SCS-I dataset used in Manuscript 1 made it 
possible to use time-to-event analysis to identify not just who was less likely to quit smoking but 
also how much longer it took certain groups to quit, which has implications for which groups to 
continue to provide intensive cessation resources over time.  
Finally, the PATH data included measures of both ever and current e-cigarette use, which 
provided information about both experimental e-cigarette users (e.g., those who used e-cigarettes 
one or two times) and those who use more frequently. These two measures of e-cigarette use 
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provide a fuller picture of the extent that cancer survivors who smoke are using e-cigarettes as a 
smoking cessation tool than if only one measure of e-cigarette use were assessed. 
 Some limitations of this dissertation relate to the measures used in each dataset. In 
Manuscript 1, the variable time since quitting was imprecisely measured because age at quitting 
was measured in discrete years, which might not reflect an accurate time of when survivors quit 
smoking. The yearly hazard ratio of quitting smoking, however, has been used in another time-
to-event analysis study106 and I incorporated the discrete nature of the data into the analyses. 
More precise measures of the length of time until quitting in days or months, rather than in years, 
may help us better understand the best windows of opportunity for intervention. Second, in SCS-
I, smoking status was assessed retrospectively at a single time point. It would be informative for 
future studies to conduct these analyses in data that contain multiple assessments of both 
psychosocial factors and smoking status over time to improve our understanding of the 
directionality of this association and to ensure more precise measurement of the timing of 
cessation. Third, in the PATH data, cancer type was self-reported, unlike in SCS-I, where cancer 
type was confirmed by medical records. Self-reported cancer diagnosis might not be as accurate 
as a confirmed cancer diagnosis, although Westmaas et al. found a strong correlation (>95%) 
between self-reported diagnosis and medical record-confirmed diagnosis in the SCS-I data.49 
This dissertation also includes limitations in generalizability of findings. First, the 
analysis in Manuscript 1 relies on data from longtime cancer survivors and the generalizability of 
any findings from this work has to be understood as applicable only to individuals who do 
survive 7-10 years post diagnosis. In the SCS-I sample, participants in Wave 1 were more likely 
to remain in Wave 3 if they were diagnosed with non-tobacco-related cancer and reported lower 
comorbid conditions at Wave 1, lower psychological distress, higher mental and physical 
 
 78 
HRQOL, and higher perceived social support. The smoking rate was low in the SCS-I Wave 3 
sample (7.8%); if the people lost to follow-up were also particularly unlikely to quit smoking and 
were perhaps heavier smokers and had worse psychosocial outcomes, had I included them in the 
analytic sample, results might have been different. Second, some analyses in Manuscripts 2 and 
3 had limited sample sizes, so null results might reflect limited power to detect smaller effects. In 
Manuscript 2, there were only 80 survivors diagnosed within two years, thus larger studies with 
more variability in length of time since diagnosis are needed to ascertain if there are greater 
differences in perceived severity of smoking between survivors of tobacco and non-tobacco-
related cancers in the time shortly after cancer treatment compared to several years after 
diagnosis. In Manuscript 3, only 99 cancer survivors reported currently using e-cigarettes so 
generalizing about the reported prevalence of different reasons for use should be done with 
caution. This sample size also precluded us from controlling for demographic characteristics 
when analyzing differences in reasons for using e-cigarettes. The samples of current e-cigarette 
users who were cancer survivors and those never diagnosed, however, were not significantly 
different in age or education—two factors related to e-cigarette use.64,65 It is possible that we did 
not find significant differences in e-cigarette use between survivors of tobacco-related and non-
tobacco-related cancers because our sample size was not large enough to detect a statistical 
difference. Larger studies of e-cigarette use and reasons for use in cancer survivors are needed, 
with a focus on differences between survivors of various cancer types.  
Reasons for using two different datasets. This dissertation relied on data from multiple 
datasets because no single dataset contained information necessary to explore all of my research 
questions. I decided to use the SCS-I dataset in Manuscript 1 of this dissertation because it had 
multiple psychosocial predictors at Wave 1 that were theoretically relevant to smoking cessation 
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in cancer survivors and it was longitudinal, which allowed me to use time-to-event analysis to 
answer my questions. SCS-I included one item on perceived severity of health problems from 
smoking, but I chose to use the PATH dataset in Manuscript 2 to examine differences in 
perceived severity between survivors of tobacco-related and non-tobacco-related cancers because 
1) PATH also contained data from recently diagnosed and long-term survivors, which allowed 
me to test for an interaction with time since diagnosis, 2) PATH had two items that measured 
perceived severity of smoking, which was more informative than one item, and 3) PATH had a 
larger sample size and included more cancer types than SCS-I. I chose to use PATH to answer 
the research questions in Manuscript 3 because this was the only dataset that included 
information on e-cigarette use and reasons for use in cancer survivors.  
6.3 Implications for Research and Practice 
Implications for Research  
The results from all three studies highlight important additional avenues of research that 
could enhance our understanding of smoking cessation in cancer survivors. First, longitudinal 
studies that track beliefs, behaviors, and smoking statuses of cancer survivors progressively over 
time would allow for more precise measurement of many of the constructs employed in this 
dissertation, and testing of some of the mediation pathways inherent in the theoretical models 
driving the studies here. For example, annual measures of smoking-related beliefs, quit intention, 
and smoking status over time would extend the research in the second manuscript to assess 
whether beliefs about smoking mediate the relationship between diagnosis of tobacco-related 
cancer and both quit intentions and successful quitting. Additionally, charting dual combustible 
and electronic cigarette use in survivors over time could improve our understanding of how e-
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cigarettes are used as cessation strategies, and whether they are effective in survivors who may 
be especially motivated to quit.  
Second, datasets that include other psychosocial constructs, such as attitudes about 
quitting smoking (i.e., barriers and benefits to quitting and benefits to smoking) and provider and 
social network actions related to cessation (e.g., whether there are other smokers in the house, 
whether survivors experienced social pressure to quit from their friends and family, attitudes and 
beliefs about quitting of the smokers’ social network, and whether clinicians advised cancer 
patients to quit and cessation strategies they recommended), could add to the research on why 
cancer type is associated with smoking cessation. Additionally, it would be informative to assess 
psychosocial constructs such as a survivor’s fatalistic beliefs—i.e., the belief that one’s own 
actions will not influence health, which can undermine health-protective behaviors in cancer 
survivors69—to explore why survivors with poor physical HRQOL particularly struggle to quit 
smoking. In the theoretical models for this dissertation, I combined constructs across several 
theories that I thought were the most pertinent in explaining why a cancer diagnosis might 
influence smoking behavior, but it is possible that theoretical constructs not included in this 
dissertation (e.g., self-efficacy for quitting, subjective norms, perceived behavioral control) could 
also be important links between cancer type, psychosocial variables, and cession. An alternative 
model building approach would have been to test all of the constructs in each theory separately 
to identify variables that might be most salient, and then combine those to produce an overall 
conceptual model. Unfortunately, key measures of all constructs of any theory were not available 




Third, intervention research could examine lingering questions about whether changing 
the predictors assessed in this dissertation actually produce expected changes in smoking. For 
example, although the first study identified physical HRQOL as a risk factor for smoking and 
delayed cessation, it is unclear whether it is a causal factor. Research could test whether 
strategies to mitigate physical symptoms in those with poor physical HRQOL (e.g., by 
incorporating acupuncture or occupational therapy to combat persistent fatigue and pain) 
increase the likelihood of successful smoking cessation. If such strategies prove ineffective, 
researchers should explore potential correlates of physical HRQOL that might be causally related 
to smoking. Similarly, randomized control trials of smoking cessation interventions could test 
whether changing beliefs about the harms of smoking—particularly among survivors of non-
tobacco-related cancers—in turn produces higher quit rates.  
Finally, qualitative studies could shed additional light on the quantitative findings in this 
dissertation. In-depth interviews with cancer survivors could further our understanding of: 1) 
why survivors with low physical HRQOL struggle to quit smoking (e.g., Which specific barriers 
to quitting do survivors with low physical HRQOL experience?), 2) how messages from 
providers and family members influence their smoking-related health beliefs, 3) survivors’ 
beliefs about the effectiveness of e-cigarettes as a cessation tool, especially as compared to other 
cessation strategies, and 4) which cessation strategies survivors tried and which have been the 
most successful.  
Implications for Practice 
The findings from all three Manuscripts have implications for clinical practice with 
cancer survivors who smoke. Having a diagnosis of a non-tobacco related cancer is associated 
with lower perceived risks from smoking and lower quit rates, so clinicians should identify and 
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discuss health problems related to smoking with all of their patients who smoke, but particularly 
with their patients diagnosed with non-tobacco-related cancers.  
Asking a few additional questions about smoking may also enhance the ability of 
clinicians to support cessation. By assessing physical HRQOL and perceived severity of smoking 
as part of routine care, clinicians can identify patients at particularly high risk to continue 
smoking and work with them to understand their risks and identify resources for cessation 
assistance. Survivors with low physical HRQOL may particularly need intensive long-term 
smoking cessation interventions that include strategies to help them manage their symptoms 
(e.g., strategies that reduce pain and fatigue).  
By asking whether smokers are trying e-cigarettes as a strategy for quitting, providers can 
also identify patients who may need additional information about the risks and potential benefits 
of e-cigarette use, and provide them with alternative evidence-based strategies. To counsel about 
this effectively, it would be worthwhile for clinicians themselves to stay abreast of the still 
emerging literature about the cessation efficacy and harms of e-cigarettes.  
6.4 Conclusions 
Quitting smoking is beneficial to the health of any person, but particularly for cancer 
survivors who are susceptible to even more health issues than the general population if they 
continue to smoke.15 Smoking cessation treatment programs in oncology settings are rare15,36 and 
the few smoking cessation interventions for cancer survivors that have been implemented have 
not been effective in influencing smoking cessation rates.37 Based on the findings from this 
dissertation, clinicians may want to assess physical HRQOL, perceived severity of smoking, and 
e-cigarette use as a quitting strategy in their patients who smoke to identify patients at 
 
 83 
particularly high risk of continued smoking and potential means for interventions that could 
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